

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 11

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following documents listed below which are also listed on Substitute Form PTO-1449 (**Exhibit B**).

This Supplemental Information Disclosure Statement is being submitted pursuant to 37 C.F.R. §1.97(b)(4) before the mailing of a first Office Action after the filing of a request for continued examination (RCE) under 37 C.F.R. §1.411. Thus, this Supplemental Information Disclosure Statement should be entered and considered.

In accordance with 37 C.F.R. §1.92(a)(2)(ii), copies of the U.S. Patents and U.S. Patent Application Publications listed herein are not provided. Accordingly, copies of documents listed below as items 1-21 are not submitted herewith. Copies of documents listed below as items 18-286 are attached hereto as **Exhibits 1-265**.

1. U.S. Patent No. 6,692,745 issued February 17, 2004 to Olson;
2. U.S. Patent No. 6,797,811 issued September 28, 2004 to Gray;
3. U.S. Patent No. 5,126,433 issued December 21, 1989 to Maddon;
4. U.S. Patent No. 5,021,409 issued June 4, 1991 to Murrer;
5. U.S. Patent No. 5,440,021 issued August 5, 1995 to Chuntharapai;
6. U.S. Patent No. 5,504,003 issued April 2, 1996 to Haodong Li;
7. U.S. Patent No. 7,118,859 issued October 10, 2006 to V.M. Litwin et al.;
8. U.S. Patent No. 7,138,119 issued November 21, 2006 to W.C. Olson et al.;

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 12

9. U.S. Patent No. 7,060,273 issued June 13, 2006 to W.C. Olson et al.;
10. U. S. Patent No. 7,122,185 issued October 17, 2006 to W.C. Olson et al.;
11. U.S. Patent No. 6,908,734 issued June 21, 2005 to T. Dragic et al.;
12. U.S. Patent No. 7,151,087 B2 issued December 19, 2006 to C. Combadiere et al.;
13. L. Wu et al., U.S. Patent Application Publication No. 2003-0166870 published December 23, 2004;
14. C. Combadiere et al., U.S. Patent Application Publication No. 2005-0118677 published June 2, 2005;
15. W.C. Olson et al., U.S. Patent Application Publication No. 2007-0031408 A1 published February 8, 2007;
16. W.C. Olson et al., U.S. Patent Application Publication No. 2007-0020280 A1 published January 25, 2007;
17. V.M. Litwin et al., U.S. Patent Application Publication No. 2007-0025983 A1 published February 1, 2007;
18. W.C. Olson et al., U.S. Patent Application Publication No. 2007-0026441 A1 published February 1, 2007;
19. G.P. Allaway et al., U.S. Patent Publication No. 2006-0233798 published October 19, 2006;
20. G.P. Allaway et al., U.S. Patent Application Publication No. 2007-0048820 A1 published March 1, 2007;

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 13

21. G.P. Allaway et al., U.S. Patent Application Publication No. 2006-0194244 published August 31, 2006;
22. February 15, 1996 Advisory Action in connection with U.S. Application Serial No. 08/169,311 (**Exhibit 1**);
23. September 13, 1995 Final Office Action in connection with U.S. Application Serial No. 08/169,311 (**Exhibit 2**);
24. November 23, 1994 Office Action in connection with U.S. Application Serial No. 08/169,311 (**Exhibit 3**);
25. August 18, 1994 Office Action in connection with U.S. Application Serial No. 08/169,311 (**Exhibit 4**);
26. July 16, 1998 Notice of Acceptance in connection with Australian Application No. 14387/95 (**Exhibit 5**);
27. November 27, 1996 Examiner's First Report in connection with Australian Application No. 14387/95 (**Exhibit 6**);
28. July 5, 2000 Notice of Acceptance in connection with Australian Application No. 62690/96 (**Exhibit 7**);
29. November 10, 1998 Examiner's First Report in connection with Australian Application No. 62690/96 (**Exhibit 8**);
30. September 14, 2006 Official Action in connection with Canadian Application No. 2,224,003 (**Exhibit 9**);
31. September 11, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3 (**Exhibit 10**) ;

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 14

32. March 8, 2006 Summons to Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 96 921 473.3 (**Exhibit 11**);
33. February 24, 2005 Provision of a Copy of the Minutes in accordance with Rule 76(4) EPC in connection with European Application No. 96 921 473.3 (**Exhibit 12**);
34. February 24, 2005 Decision to Refuse a European Patent Application in connection with European Application No. 96 921 473.3 (**Exhibit 13**);
35. August 30, 2004 Summons to Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 96 921 473.3 (**Exhibit 14**);
36. December 19, 2002 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3 (**Exhibit 15**);
37. July 6, 2001 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3 (**Exhibit 16**);
38. December 20, 1999 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/973,601 (**Exhibit 17**);
39. August 3, 1999 Advisory Action in connection with U.S. Application Serial No. 08/973,601 (**Exhibit 18**);
40. March 25, 1999 Office Action in connection with U.S. Application Serial No. 08/973,601 (**Exhibit 19**);
41. June 24, 1998 Office Action in connection with U.S. Application Serial No. 08/973,601 (**Exhibit 20**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 15

42. January 11, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/412,284 (**Exhibit 21**);
43. December 2, 2003 Final Office Action in connection with U.S. Application Serial No. 09/412,284 (**Exhibit 22**);
44. February 3, 2003 Office Action in connection with U.S. Application Serial No. 09/412,284 (**Exhibit 23**);
45. April 8, 2002 Advisory Action in connection with U.S. Application Serial No. 09/412,284 (**Exhibit 24**);
46. September 11, 2001 Final Office Action in connection with U.S. Application Serial No. 09/412,284 (**Exhibit 25**);
47. December 19, 2000 Office Action in connection with U.S. Application Serial No. 09/412,284 (**Exhibit 26**);
48. April 18, 2007 Office Action in connection with U.S. Application Serial No. 11/258,963 (**Exhibit 27**);
49. December 26, 2006 Office Action in connection with U.S. Application Serial No. 11/258,963 (**Exhibit 28**);
50. February 8, 2007 Office Action in connection with U.S. Application Serial No. 09/904,356 (**Exhibit 29**);
51. May 2, 2006 Final Office Action in connection with U.S. Application Serial No. 09/904,356 (**Exhibit 30**);
52. October 12, 2005 Office Action in connection with U.S. Application Serial No. 09/904,356 (**Exhibit 31**);
53. July 29, 2005 Advisory Action in connection with U.S. Application Serial No. 09/904,356 (**Exhibit 32**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 16

54. November 17, 2004 Final Office Action in connection with U.S. Application Serial No. 09/904,356 (**Exhibit 33**);
55. July 1, 2003 Office Action in connection with U.S. Application Serial No. 09/904,356 (**Exhibit 34**);
56. September 29, 2003 Advisory Action in connection with U.S. Application Serial No. 09/118,415 (**Exhibit 35**);
57. January 28, 2003 Final Office Action in connection with U.S. Application Serial No. 09/118,415 (**Exhibit 36**);
58. April 9, 2002 Office Action in connection with U.S. Application Serial No. 09/118,415 (**Exhibit 37**);
59. August 14, 2001 Advisory Action in connection with U.S. Application Serial No. 09/118,415 (**Exhibit 38**);
60. November 24, 2000 Final Office Action in connection with U.S. Application Serial No. 09/118,415 (**Exhibit 39**);
61. February 11, 2000 Office Action in connection with U.S. Application Serial No. 09/118,415 (**Exhibit 40**);
62. August 3, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/891,062 (**Exhibit 41**);
63. July 17, 2006 Notice of Allowability in connection with U.S. Application Serial No. 09/891,062 (**Exhibit 42**);
64. May 18, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/891,062 (**Exhibit 43**);
65. August 8, 2005 Office Action in connection with U.S. Application Serial No. 09/891,062 (**Exhibit 44**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 17

66. March 21, 2005 Office Action in connection with U.S. Application Serial No. 09/891,062 (**Exhibit 45**);
67. May 28, 2004 Advisory Action in connection with U.S. Application Serial No. 09/891,062 (**Exhibit 46**);
68. September 24, 2003 Final Office Action in connection with U.S. Application Serial No. 09/891,062 (**Exhibit 47**);
69. December 18, 2002 Office Action in connection with U.S. Application Serial No. 09/891,062 (**Exhibit 48**);
70. April 30, 2007 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 11/544,346 (**Exhibit 49**);
71. March 3, 1997 Office Action in connection with U.S. Application Serial No. 08/627,684 (**Exhibit 50**);
72. June 23, 1997 Office Action in connection with U.S. Application Serial No. 08/663,616 (**Exhibit 51**);
73. March 13, 1997 Office Action in connection with U.S. Application Serial No. 08/673,682 (**Exhibit 52**);
74. November 28, 2000 Notice of Acceptance in connection with Australian Application No. 26074/97 (**Exhibit 53**);
75. July 13, 1999 Examiner's First Report in connection with Australian Application No. 26074/97 (**Exhibit 54**);
76. October 23, 2006 Official Action in connection with Canadian Application No. 2,250,829 (**Exhibit 55**);
77. May 27, 2005 Official Action in connection with Canadian Application No. 2,250,829 (**Exhibit 56**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 18

78. May 4, 2007 Summons to Attend Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 97917856.3 (**Exhibit 57**);
79. January 27, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3 (**Exhibit 58**);
80. October 21, 2005 Communication Pursuant to Article 115(2) EPC in connection with European Application No. 97917856.3 (**Exhibit 59**);
81. April 1, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3 (**Exhibit 60**);
82. August 5, 2004 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3 (**Exhibit 61**);
83. January 27, 2004 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3 (**Exhibit 62**);
84. May 9, 2003 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3 (**Exhibit 63**);
85. March 6, 2002 Search Report Communication in connection with European Application No. 97917856.3 (**Exhibit 64**);
86. February 27, 2007 Notification of Reasons for Rejection in connection with Japanese Application No. 535610/97 (English translation) (**Exhibit 65**);
87. May 19, 2006 Examiner's First Report in connection with Australian Application No. 2004233505 (**Exhibit 66**);
88. July 26, 2004 Notice of Acceptance in connection with Australian Application No. 35106/01 (**Exhibit 67**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 19

89. July 5, 2004 Examiner's Second Report in connection with Australian Application No. 35106/01 (**Exhibit 68**);
90. November 1, 2002 Examiner's First Report in connection with Australian Application No. 35106/01 (**Exhibit 69**);
91. December 4, 2001 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/831,823 (**Exhibit 70**);
92. January 16, 2001 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/831,823 (**Exhibit 71**);
93. September 26, 2000 Advisory Action in connection with U.S. Application Serial No. 08/831,823 (**Exhibit 72**);
94. April 11, 2000 Final Office Action in connection with U.S. Application Serial No. 08/831,823 (**Exhibit 73**);
95. July 21, 1999 Final Office Action in connection with U.S. Application Serial No. 08/831,823 (**Exhibit 74**);
96. December 21, 1998 Office Action in connection with U.S. Application Serial No. 08/831,823 (**Exhibit 75**);
97. August 17, 1998 Office Action in connection with U.S. Application Serial No. 08/831,823 (**Exhibit 76**);
98. June 15, 2006 Final Office Action in connection with U.S. Application Serial No. 09/888,938 (**Exhibit 77**);
99. September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938 (**Exhibit 78**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 20

100. August 4, 2004 Office Action in connection with U.S. Application Serial No. 09/888,938 (**Exhibit 79**);
101. May 5, 2004 Office Action in connection with U.S. Application Serial No. 09/888,938 (**Exhibit 80**);
102. June 22, 1999 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/876,078 (**Exhibit 81**);
103. December 21, 1998 Final Office Action in connection with U.S. Application Serial No. 08/876,078 (**Exhibit 82**);
104. March 23, 1998 Office Action in connection with U.S. Application Serial No. 08/876,078 (**Exhibit 83**);
105. June 16, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 98 931 261.6 (**Exhibit 84**);
106. June 17, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 98 931 261.6 (**Exhibit 85**);
107. October 17, 2006 Final Office Action in connection with U.S. Application Serial No. 09/460,216 (**Exhibit 86**);
108. February 3, 2006 Office Action in connection with U.S. Application Serial No. 09/460,216 (**Exhibit 87**);
109. July 29, 2005 Advisory Action in connection with U.S. Application Serial No. 09/460,216 (**Exhibit 88**);
110. February 09, 2005 Final Office Action in connection with U.S. Application Serial No. 09/460,216 (**Exhibit 89**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 21

111. September 26, 2003 Advisory Action in connection with U.S. Application Serial No. 09/460,216 (**Exhibit 90**);
112. February 27, 2003 Final Office Action in connection with U.S. Application Serial No. 09/460,216 (**Exhibit 91**);
113. October 2, 2001 Office Action in connection with U.S. Application Serial No. 09/460,216 (**Exhibit 92**);
114. September 9, 2002 Notice of Acceptance in connection with Australian Application No. 81426/98 (**Exhibit 93**);
115. February 27, 2002 Examiner's Second Report in connection with Australian Application No. 81426/98 (**Exhibit 94**);
116. February 21, 2001 Examiner's First Report in connection with Australian Application No. 81426/98 (**Exhibit 95**);
117. February 4, 1997 Office Action in connection with U.S. Application Serial No. 08/665,090 (**Exhibit 96**);
118. August 29, 2000 Notice of Allowance and Allowability in connection with 08/874,618 (**Exhibit 97**);
119. November 19, 1999 Office Action in connection with U.S. Application Serial No. 08/874,618 (**Exhibit 98**);
120. May 24, 1999 Final Office Action in connection with U.S. Application Serial No. 08/874,618 (**Exhibit 99**);
121. September 2, 1998 Office Action in connection with U.S. Application Serial No. 08/874,618 (**Exhibit 100**);
122. December 13, 2005 Final Office Action in connection with U.S. Application Serial No. 09/724,105 (**Exhibit 101**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 22

123. March 23, 2005 Office Action in connection with U.S. Application Serial No. 09/724,105 (**Exhibit 102**);
124. September 23, 2004 Office Action in connection with U.S. Application Serial No. 09/724,105 (**Exhibit 103**);
125. May 19, 2004 Office Action in connection with U.S. Application Serial No. 09/724,105 (**Exhibit 104**);
126. December 19, 2006 Office Action in connection with U.S. Application Serial No. 11/400,497 (**Exhibit 105**);
127. August 8, 2006 Office Action in connection with U.S. Application Serial No. 11/400,497 (**Exhibit 106**);
128. May 29, 2001 Notice of Acceptance in connection with Australian Application No. 34026/97 (**Exhibit 107**);
129. September 28, 1999 Examiner's First Report in connection with Australian Application No. 34026/97 (**Exhibit 108**);
130. November 10, 2006 Official Action in connection with Canadian Application No. 2,257,991 (**Exhibit 109**);
131. May 23, 2005 Communications Pursuant to Article 96(2) EPC in connection with European Application No. 97 930 120.7 (**Exhibit 110**);
132. November 17, 2004 Communication of partial European search report under Rule 45 EPC in connection with European Application No. 97 930 120.7 (**Exhibit 111**);
133. September 9, 2004 Communication of partial European search report under Rule 46(1) EPC in connection with European Application No. 97 930 120.7 (**Exhibit 112**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 23

134. October 17, 2006 Notification of Reasons for Rejection in connection with Japanese Application No. 501895/98 (English translation) (**Exhibit 113**);
135. April 5, 2004 Notice of Acceptance in connection with Australian Application No. 21996/00 (**Exhibit 114**);
136. February 5, 2003 Examiner's First Report in connection with Australian Application No. 21996/00 (**Exhibit 115**);
137. March 29, 2006 Examiner's First Report in connection with Australian Application No. 20004205164 (**Exhibit 116**);
138. March 29, 2006 Examiner's First Report in connection with Australian Application No. 20004205165 (**Exhibit 117**);
139. March 1, 2006 Communication under Rule 51(4) EPC in connection with European Application No. 99 966 466.7 (**Exhibit 118**);
140. January 10, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 99 966 466.7 (**Exhibit 119**);
141. October 14, 2004 Communication Pursuant to Article 96(1) and Rule 51(1) EPC in connection with European Application No. 99 966 466.7 (**Exhibit 120**);
142. January 18, 2007 Office communication in connection with Mexican Application No. 1006097 (**Exhibit 121**);
143. October 13, 2005 Office communication in connection with Mexican Application No. 1006097 (**Exhibit 122**);
144. February 6, 2007 Notice of Allowability in connection with U.S. Application Serial No. 09/464,902 (**Exhibit 123**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 24

145. January 8, 2007 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/464,902 (**Exhibit 124**);
146. April 19, 2006 Office Action in connection with U.S. Application Serial No. 09/464,902 (**Exhibit 125**);
147. October 21, 2005 Office Action in connection with U.S. Application Serial No. 09/464,902 (**Exhibit 126**);
148. June 15, 2005 Advisory Action in connection with U.S. Application Serial No. 09/464,902 (**Exhibit 127**);
149. January 13, 2005 Final Office Action in connection with U.S. Application Serial No. 09/464,902 (**Exhibit 128**);
150. April 2, 2004 Office Action in connection with U.S. Application Serial No. 09/464,902 (**Exhibit 129**);
151. October 21, 2003 Office Action in connection with U.S. Application Serial No. 09/464,902 (**Exhibit 130**);
152. September 25, 2001 Office Action in connection with U.S. Application Serial No. 09/464,902 (**Exhibit 131**);
153. August 7, 2006 Office Action in connection with U.S. Application Serial No. 09/594,983 (**Exhibit 132**);
154. March 24, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/594,983 (**Exhibit 133**);
155. July 11, 2005 Final Office Action in connection with U.S. Application Serial No. 09/594,983 (**Exhibit 134**);
156. August 25, 2004 Office Action in connection with U.S. Application Serial No. 09/594,983 (**Exhibit 135**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 25

157. September 23, 2003 Notice of Allowability in connection with U.S. Application Serial No. 09/594,983 (**Exhibit 136**);
158. December 3, 2002 Final Office Action in connection with U.S. Application Serial No. 09/594,983 (**Exhibit 137**);
159. March 13, 2002 Office Action in connection with U.S. Application Serial No. 09/594,983 (**Exhibit 138**);
160. September 28, 2001 Office Action in connection with U.S. Application Serial No. 09/594,983 (**Exhibit 139**);
161. December 19, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/763,545 (**Exhibit 140**);
162. July 26, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545 (**Exhibit 141**);
163. June 13, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545 (**Exhibit 142**);
164. February 16, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545 (**Exhibit 143**);
165. May 16, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/371,483 (**Exhibit 144**);
166. October 24, 2006 Office Action in connection with U.S. Application Serial No. 10/371,483 (**Exhibit 145**);
167. January 29, 2007 Examiner's First Report in connection Australian Application No. 2003217674 (**Exhibit 146**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 26

168. February 22, 2007 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 03 713 632.2 (**Exhibit 147**);
169. April 21, 2006 Supplementary European search report under Article 157(2)(a) in connection with European Application No. 03 713 632.2 (**Exhibit 148**);
170. October 12, 2004 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 03 713 632.2 (**Exhibit 149**);
171. March 14, 2006 Examination Report in connection with New Zealand Application No. 534947 (**Exhibit 150**);
172. February 21, 2003 Official Action in connection with Russian Federation Application No. 2004128252/13(030609) (English Translation) (**Exhibit 151**);
173. September 29, 2006 Grant of Patent in connection with Singaporean Application No. 200404610-8 (**Exhibit 152**);
174. August 7, 2002 Office Action in connection with U.S. Application Serial No. 09/663,219 (**Exhibit 153**);
175. January 5, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/912,824 (**Exhibit 154**);
176. January 26, 2005 Final Office Action in connection with U.S. Application Serial No. 09/912,824 (**Exhibit 155**);
177. April 20, 2004 Office Action in connection with U.S. Application Serial No. 09/912,824 (**Exhibit 156**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 27

178. July 2, 2003 Office Action in connection with U.S. Application Serial No. 09/912,824 (**Exhibit 157**);
179. July 3, 2006 Notice of Acceptance in connection with Australian Application No. 2001290925 (**Exhibit 158**);
180. June 28, 2005 Examiner's First Report in connection with Australian Application No. 2001290925 (**Exhibit 159**);
181. May 24, 2006 Supplementary European search report under Article 157(2)(a) EPC in connection with European Application No. 01970984.9 (**Exhibit 160**);
182. February 28, 2005 Formalities Examination in connection with European Application No. 01970984.9 (**Exhibit 161**);
183. May 2, 2003 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 01970984.9 (**Exhibit 162**);
184. October 25, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/828,615 (**Exhibit 163**);
185. September 13, 2005 Office Action in connection with U.S. Application Serial No. 09/828,615 (**Exhibit 164**);
186. March 2, 2005 Office Action in connection with U.S. Application Serial No. 09/828,615 (**Exhibit 165**);
187. September 17, 2004 Final Office Action in connection with U.S. Application Serial No. 09/828,615 (**Exhibit 166**);
188. February 23, 2004 Office Action in connection with U.S. Application Serial No. 09/828,615 (**Exhibit 167**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 28

189. September 9, 2003 Advisory Action in connection with U.S. Application Serial No. 09/828,615 (**Exhibit 168**);
190. February 21, 2003 Final Office Action in connection with U.S. Application Serial No. 09/828,615 (**Exhibit 169**);
191. June 25, 2002 Office Action in connection with U.S. Application Serial No. 09/828,615 (**Exhibit 170**);
192. June 9, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/116,797 (**Exhibit 171**);
193. April 25, 2005 Final Office Action in connection with U.S. Application Serial No. 10/116,797 (**Exhibit 172**);
194. October 6, 2004 Office Action in connection with U.S. Application Serial No. 10/116,797 (**Exhibit 173**);
195. February 9, 2004 Office Action in connection with U.S. Application Serial No. 10/116,797 (**Exhibit 174**);
196. September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938 (**Exhibit 175**);
197. W.C. Olson et al., U.S. Patent Application Serial No. 11/581,944 filed October 16, 2006 (**Exhibit 176**);
198. PCT International Application Publication No WO 07/014114, published February 1, 2007 (**Exhibit 177**);
199. PCT International Application Publication No. WO 94/22477, published October 13, 1994 (**Exhibit 178**);
200. PCT International Preliminary Examination Report issued October 18, 1996 for International Application Publication No. WO 95/16789 (**Exhibit 179**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 29

201. PCT International Preliminary Examination Report issued September 5, 1997 for International Application Publication No. WO 96/41020 (**Exhibit 180**);
202. PCT International Preliminary Examination Report issued October 16, 1999 for International Application Publication No. WO 97/47319 (**Exhibit 181**);
203. PCT International Preliminary Examination Report issued September 28, 2005 for International Application Publication No. WO 03/072766 (**Exhibit 182**);
204. PCT International Preliminary Examination Report issued April 5, 2006 for International Application Publication No. WO 03/072766 (**Exhibit 183**);
205. PCT International Preliminary Examination Report issued February 15, 2001 for International Application Publication No. WO 00/35409 (**Exhibit 184**);
206. PCT International Preliminary Examination Report issued December 24, 2003 for International Application Publication No. WO 02/083172 (**Exhibit 185**);
207. PCT International Search Report issued March 13, 1995 for International Application Publication No. WO 95/16789 (**Exhibit 186**);
208. PCT International Search Report issued October 10, 1996 for International Application Publication No. WO 96/41020 (**Exhibit 187**);
209. PCT International Search Report issued June 9, 1997 for International Application Publication No. WO 97/26009 (**Exhibit 188**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 30

210. PCT International Search Report issued September 3, 1997 for International Application Publication No. WO 97/47319 (**Exhibit 189**);
211. PCT International Search Report issued September 3, 1997 for International Application Publication No. WO 97/47318 (**Exhibit 190**);
212. PCT International Search Report issued June 7, 2000 for International Application Publication No. WO 00/35409 (**Exhibit 191**);
213. PCT International Search Report issued August 13, 2003 for International Application Publication No. WO 03/072766 (**Exhibit 192**);
214. PCT International Search Report issued April 23, 2002 for International Application Publication No. WO 02/22077 (**Exhibit 193**);
215. PCT International Search Report issued July 31, 2003 for International Application Publication No. WO 02/083172 (**Exhibit 194**);
216. PCT Written Opinion issued May 25, 2005 in connection with International Application Publication No. WO 03/072766 (**Exhibit 195**);
217. European Supplementary Search Report issued February 24, 2000 for European Patent Application No. 96921473.3 (**Exhibit 196**);
218. European Supplementary Search Report issued September 5, 2002 for European Patent Application No. 95905987.4 (**Exhibit 197**);
219. European Supplementary Search Report issued April 27, 2006 for European Patent Application No. 01970984.9 (**Exhibit 198**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 31

- 220. European Supplementary Search Report issued April 21, 2006 for European Application No. 03713632.2 (**Exhibit 199**);
- 221. European Supplementary Partial Search Report issued August 26, 2004 for European Patent Application No. 97930120.7 (**Exhibit 200**);
- 222. European Supplementary Partial Search Report issued November 8, 2004 for European Patent Application No. 97930120.7 (**Exhibit 201**);
- 223. European Supplementary Partial Search Report issued September 27, 2004 for European Application No. 99966466 (**Exhibit 202**);
- 224. European Patent Office Communication issued November 11, 2004 in connection with European Patent Application No. 97930120.7 (**Exhibit 203**);
- 225. Genbank Sequence Report, Accession Entry X91942 for G. domesticus CpG island sequence 20, submitted October 4, 2005 (**Exhibit 204**);
- 226. Janeway and Travers (1994). Immunobiology, Current Biology Ltd., San Francisco. Pp. 10:27-10:42 (**Exhibit 205**);
- 227. Stryer (1988). Biochemistry, 3rd edition. Pp. 984-988 (**Exhibit 206**);
- 228. December 17, 2003 Third Party Observations in connection with European Application No. 97904948.3 (**Exhibit 207**);
- 229. February 27, 2004 Third Party Observations in connection with European Application No. 97904948.3 (**Exhibit 208**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 32

230. Alkhatib, G., et al. (1996). CC CKR5: A RANTES, MIP-1a, MIP-1 β Receptor As A Fusion Cofactor For Macrophage-Tropic HIV-1. Science, 272:1955-1958 (**Exhibit 209**);
231. Alkhatib, G., et al. (1997). HIV Co-Receptor Activity Of CCR5 And Its Inhibition By Chemokines: Independence From G Protein Signaling And Importance Of Co-Receptor Down Modulation. Virology, 234:340-348 (**Exhibit 210**);
232. Arenzana-Selsdedos, F., et al. (1996). HIV Blocked By Chemokine Antagonist. Nature, 383:400 (**Exhibit 211**);
233. Back, D.J. (1999). Pharmacological Issues Relating To Viral Resistance. Infection, 27(Suppl.2):S42-S44 (**Exhibit 212**);
234. Balzarini, et al. (1995). Suppression Of The Breakthrough Of HIV-1 In Cell Culture By Thiocarboxanilide Derivatives When Used Individually Or In Combination With Other HIV-1-Specific Inhibitors. Proc. Natl. Acad. Sci., 92:5470-5474 (**Exhibit 213**);
235. Bleul, C.C., et al. (1991). The Lymphocyte Chemoattractant SDF-1 Is A Ligand For LESTR/Fusion And Blocks HIV-1 Entry. Nature, 382:829-832 (**Exhibit 214**);
236. Brenner, T.J., et al. (1996). Relation Between HIV-1 Syncytium Inhibition Antibodies And Clinical Outcome In Children. Lancet, 337:1001-1005 (**Exhibit 215**);
237. Broder, et al. (1996). HIV And The 7-Transmembrane Domain Receptors. Pathobiology, 64(4):171-179 (**Exhibit 216**);
238. Choe, H., et al. (1996). The Beta-Chemokine Receptors CCR3 And CCR5 Facilitate Infection By Primary HIV-1 Isolates. Cell, 85:1135-1148 (**Exhibit 217**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 33

239. Cocchi, F. (1995). Identification Of RANTES, MIP-1alpha And MIP-1beta As The Major HIV-Suppressive Factors Produced By CD8+ T-Cells. Science, 270:1811-1815 (**Exhibit 218**);
240. Cruse, et al. (1995). Illustrated Dictionary Of Immunology, CRC Press, Inc, Boca Raton, FL., 143:QR180.4.C78 (**Exhibit 219**);
241. Daar, E.S. (1990). High Concentrations Of Recombinant Soluble CD4 Are Required To Neutralize Primary Human Immunodeficiency Virus Type 1 Isolates. Proc. Natl. Acad. Sci., 87:6574-6578 (**Exhibit 220**);
242. De Clerq, et al. (1992). Potent And Selective Inhibition Of Human Immunodeficiency Virus (HIV)-1 and HIV-2 Replication By A Class Of Bicyclams Interacting With A Virus Uncoating Event. Proc. Natl. Acad. Sci., 89:5286-5290 (**Exhibit 221**);
243. De Clerq, et al. (1994). Highly Potent And Selective Inhibition Of Human Immunodeficiency Virus By The Bicyclam Derivative JM3100. Antimicrobial Agents and Chemotherapy, 38:668-674 (**Exhibit 222**);
244. De Clerq, et al. (1995). Antiviral Therapy For Human Immunodeficiency Virus Infections. J. Clin. Microbiol. Rev., 8(2):200-239 (**Exhibit 223**);
245. Deng, H., et al. (1996). Identification Of A Major Co-Receptor For Primary Isolates Of HIV-1. Nature, 381:661-666 (**Exhibit 224**);
246. Dikic (1996). Regulation of HIV-1 Infection by Chemokine Receptors. Acta. Med. Croatica, 50:163-168 (**Exhibit 225**);
247. Doranz, B.J., et al. (1996). A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin And Beta-Chemokine Receptors CKR-5, CKR-3 And CKR-2b As Fusion Cofactors. Cell, 85:1149-1158 (**Exhibit 226**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 34

248. Doranz, B.J., et al. (1997). A Small Molecule Inhibitor Directed Against The Chemokine Receptor CXCR4 Prevents Its Use As An HIV-1 Co-Receptor. J. Ex. Med., 186:1395-1400 (**Exhibit 227**);
249. Dragic, T.V., et al. (1996). HIV-1 Entry Into CD4+Cells Is Mediated By The Chemokine Receptor CC-CKR-5. Nature, 381:667-673 (**Exhibit 228**);
250. Fahey, J.L., et al. (1992). Status Of Immune-Based Therapies In HIV Infection And AIDS. Clin. Exp. Immunol., 88:1-5 (**Exhibit 229**)
251. Feng, Y., et al. (1996). HIV-1 Entry Cofactor: Functional cDNA Cloning Of A Seven-Transmembrane, g Protein-Coupled Receptor. Science, 272:872-877 (**Exhibit 230**);
252. Flexner, C. and Hendrix, C. (1997). "Pharmacology Of Antiretroviral Agents", in AIDS: Biology, Diagnosis, Treatment And Prevention, 4th Edition, De Vita V., et al. eds., Lippincott-Raven Publishers. Pp. 479-493 (**Exhibit 231**);
253. Fox, J.L. (1994). No Winners Against Aids. Bio/Technology, 12:128 (**Exhibit 232**);
254. Gait, M.J and Karn, J. (1995). Progress In anti-HIV Structure Based Drug Design. TIBTECH, 13:430-438 (**Exhibit 233**);
255. Gong, J.H., et al. (1995). Antagonists Of Monocyte Chemoattractant Protein 1 Identified By Modification Of Functionally Critical NH2-Terminal Residues. J. Exp. Med., 181:631-640 (**Exhibit 234**);
256. Gong, J.H., et al. (1996). RANTES And MCP-3 Antagonists Bind Multiple Chemokine Receptors. J. Biol. Chem., 371:10521-10527 (**Exhibit 235**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 35

257. Hattori, T., et al. (1989). Involvement Of Trypsin-Related Cellular Protease(S) In Human Immunodeficiency Virus Type 1 Infection. FEBS Letters, 248:48-52 (**Exhibit 236**);
258. Haynes, B.F. (1996). Updates On The Issues Of HIV Vaccine Development. Ann. Med., 28:39-41 (**Exhibit 237**);
259. Howard, O.M.Z., et al. (1998). Small Molecule Inhibitor Of HIV-1 Cell Fusion Blocks Chemokine Receptor-Mediated Fusion. J. Leuk. Biol., 64:6-13 (**Exhibit 238**);
260. Jones, S.A., et al. (1997). Chemokine Antagonists That Discriminate Between Interleukin-8 Receptors. J. Biol. Chem., 272:16166-16199 (**Exhibit 239**);
261. Klotman, et al. (1995). Transgenic Models Of HIV-1. AIDS, 9(4):313-324 (**Exhibit 240**);
262. Levy, J.A. (1996). Controlling HIV Pathogenesis: The Role Of The Non-Cytotoxic Anti-HIV Response Of CD8+ Cells. Immunology Today, 17:217-224 (**Exhibit 241**);
263. Litwin, V.M., et al. (1996). Human Immunodeficiency Virus Type 1 Membrane Fusion Mediated By A Laboratory-Adapted Strain And A Primary Isolate Analyzed By Resonance Energy Transfer. J. Virol., 70(9):6437-6441 (**Exhibit 242**);
264. Loetscher, M., et al. (1994). Cloning Of A Human Seven-Transmembrane Domain Receptor, LESTR, That Is Highly Expressed In Leukocytes. J. Biol. Chem., 269:232-237 (**Exhibit 243**);
265. McKnight, A.D., et al. (1997). Inhibition Of Human Immunodeficiency Virus Fusion By A Monoclonal Antibody To A Coreceptor (CXCR4) Is Both Cell Type And Virus Strain Dependent. J. Virol., 71:1692-1696 (**Exhibit 244**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed: December 13, 1999
Page 36

266. Mellors, J.W. (1996). Closing In On Human Immunodeficiency Virus-1. *Nature Medicine*, 2(3):274-275 (**Exhibit 245**);
267. Moser, B., et al. (1993). Interleukin-8 Antagonists Generated By N-Terminal Modification. *J. Biol. Chem.*, 268:7125-7128 (**Exhibit 246**);
268. Oberg, B and Vrang, L. (1990). Screening for new agents. *Eur. J. Clin. Microbiol. Infect. Dis.*, 9(7):466-471 (**Exhibit 247**);
269. Oberlin, E., et al. (1996). The CXC Chemokine SDF-1 is the Ligand for LESTR/fusion and prevents infection by T-cell-line-adapted HIV-1. *Nature*, 382: 833-835 (**Exhibit 248**);
270. Oellerich, M., (1984). Enzyme-Immunoassay: A Review. *J. Clin. Chem. Clin. Biochem.*, 22(12):895-904 (**Exhibit 249**);
271. Proudfoot, et al. (1999). Chemokine Receptors: Future Therapeutic Targets For HIV. *Biochem. Pharmacol.*, 57:451-463 (**Exhibit 250**);
272. Proudfoot, et al. (2000). The Strategy Of Blocking The Chemokine System To Combat Disease. *Immunol. Rev.*, 177:246- 256 (**Exhibit 251**);
273. Raport, C.J., et al. (1996). New Members Of The Chemokine Receptor Gene Family. *Journal of Leukocyte Biology*, 59:18-23 (**Exhibit 252**);
274. Raport, C.J., et al. (1996). AAC50598 submitted to NCBI on April 12, 1996 (CC Chemokine Receptor 5 sequence) (**Exhibit 253**);
275. Richman, D.D. (1996). Antiretroviral Drug-Resistance: Mechanisms, Pathogenesis, Clinical Significance. *Antivir. Chemother.*, 4:383-395 (**Exhibit 254**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed December 13, 1999
Page 37

276. Samson, M., et al. (1996). Molecular Cloning And Functional Expression Of A New Human CC-Chemokine Receptor Gene. Biochem., 35:3362-3367 (**Exhibit 255**);
277. Scarlatti, et al. (1997). In Vivo Evolution Of HIV-1 Co-Receptor Usage And Sensitivity To Chemokine-Mediated Suppression. Nature Medicine, 3(11):A2581259-1265 (**Exhibit 256**);
278. Simmons, G., et al. (1997). Potent Inhibition Of HIV-1 Infectivity In Macropages And Lymphocytes By A Novel CCR5 Antagonist. Science, 276:276-279 (**Exhibit 257**);
279. Szabo, et al. (1992). Cd4 Changes Conformation Upon Ligand Binding. J. Immunol. 149(11):3596-3604 (**Exhibit 258**);
280. Trkola, A., et al. (1996). CD-4 Dependent, Antibody Sensitive Interactions Between HIV-1 And Its Co-Receptor CCR-5. Nature, 384-187 (**Exhibit 259**);
281. Wells, T.N.C., et al. (1996). Selectivity And Antagonism Of Chemokine Receptors. Journal of Leukocyte Biology, 59:53-60 (**Exhibit 260**);
282. Wu, et al. (1997). CCR5 Levels And Expression Pattern Correlate With Infectability By Macrophagetropic HIV-1 In Vitro. J. Exp. Med., 185(9):1681-1691 (**Exhibit 261**);
283. Wu, L., et al. (1996). CD4-Induced Interaction Of Primary HIV-1 gp120 Glycoproteins With The Chemokine Receptor CCR-5. Nature, 384:179-183 (**Exhibit 262**);
284. Yarchoan, et al. (1988). "Clinical Aspects Of Infection With AIDS Retrovirus: Acute HIV Infection Persistent Generalized Lymphadenopathy And AIDS-Related Complex", in AIDS: Etiology, Diagnosis, Treatment and Prevention, De Vita, et al., eds.,

Applicants: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed: December 13, 1999
Page 38

Lippincott-Raven Publishers, Philadelphia. Pp.107-109 (**Exhibit 263**);

285. Yarchoan, R. and Broder, S. (1992). Correlations Between The In Vitro And The In Vivo Activity Of Anti-HIV Agents: Implications For Future Drug Development. J. Enzyme Inhibit., 6:99-11 (**Exhibit 264**); and

286. Zhang, Y.J., et al. (1994). Structure / Activity Analysis Of Human Monocyte Chemoattractant Protein-1 (MCP-1) By Mutagenesis. J. Biol. Chem., 269:15918-15924 (**Exhibit 265**).


No fee, other than the \$1,080.00 fee for a five-month extension of time and the \$395.00 fee for filing an RCE, is deemed necessary in filing this Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



John P. White Date
Reg. No. 28,678

Exhibit A

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark Office

Application Number	09/460,216
Filing Date	December 13, 1999
First Named Inventor	Graham P. Allaway et al.
Art Unit	1648
Examiner Name	Jeffrey S. Parkin
Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		U.S. 6,025,154	10-10-2004	Y. Li et al.
		U.S. 6,265,184	07-24-2001	P.W. Gray et al.
		U.S. 6,268,477	07-31-2002	P.W. Gray et al.
		U.S. 6,488,375	09-10-2002	M. Samson et al.
		U.S. 6,511,826	01-28-2003	Y. Li et al.
		U.S. 6,692,938	02-17-2004	M. Samson et al.
		U.S. 6,743,594	06-01-2004	Y. Li et al.
		U.S. 6,972,126	12-06-2005	G.P. Allaway et al.
		U.S. 6,800,447	10-05-2004	M. Samson et al.
		U.S. 6,800,729	10-05-2004	Y. Li et al.
		U.S. 5,449,608	09-12-1995	N. Young et al.
		U.S. 6,261,763 B1	07-17-2001	G.P. Allaway et al.
		U.S. 6,528,625	03-04-2003	L. Wu et al.
		U.S. 6,930,174	08-16-2005	M. Samson et al.
		U.S. 6,100,087	08-08-2000	J. Rossi et al.
		U.S. 5,939,320	08-17-1999	D. Littman et al.
		U.S. 6,258,527	07-10-2001	D. Littman et al.
		U.S. 6,258,782	07-10-2001	S. Barney et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		WO 92/01451	02-06-1992		
		WO 95/16789	06-22-1995		
		WO 97/28258	08-07-1997		
		WO 97/44462	11-27-1997		
		WO 98/18826	05-07-1998		
		WO 01/55439	08-02-2001		

EXAMINER
SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Applicants: G.P. Allaway, et al.
Serial No.: 09/460,216
Filed: December 13, 1999
Exhibit A

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		U.S. 6,692,938	02-17-2004	M. Samson et al.
		U.S. 5,071,964	12-10-1991	M. Dustin et al.
		U.S. 5,091,513	02-25-1992	J. Huston et al.
		U.S. 5,215,913	06-01-1993	M.R. Posner et al.
		U.S. 5,225,539	07-06-1993	G.P. Winter et al.
		U.S. 5,603,933	02-18-1997	V.A. Dwyer et al.
		U.S. 5,668,149	09-16-1997	S. Oroszlan et al.
		U.S. 5,817,767	10-06-1998	G.P. Allaway et al.
		U.S. 5,854,400	12-29-1988	T. Chang et al.
		U.S. 4,886,743	12-12-1989	L.E. Hood et al.
		U.S. 2003/0023044	01-30-2003	Y. Li et al.
		U.S. 2005/0260565	11-24-2005	P.W. Gray et al.
		U.S. 2005/0118677	06-02-2005	P.W. Gray et al.
		U.S. 2003/0166870	09-04-2003	L. Wu et al.
		U.S. 2004/0259785	12-23-2004	C. Combadiere et al.
		U.S. 2003/0195348	10-16-2003	C. Combadiere et al.
		U.S. 2003/0096221	05-22-2003	D. Littman et al.
		U.S. 2003/0003440	01-02-2003	L. Lopalco et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		WO 02/064612	08-22-2002		
		WO 01/58915	08-16-2001		
		WO 01/58916	08-16-2001		
		WO 96/39437	12-12-1996		
		WO 97/22698	06-26-1997		
		WO 97/44055	11-27-1997		
		WO 97/032019	09-04-1997		

EXAMINER
SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark Office

Application Number	09/460,216
Filing Date	December 13, 1999
First Named Inventor	Graham P. Allaway et al.
Art Unit	1648
Examiner Name	Jeffrey S. Parkin
Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		U.S. 2002/0150888	10-17-2002	P.W. Gray et al.
		U.S. 2004/0161739	08-19-2004	M. Samson et al.
		U.S. 2004/0230037	11-18-2004	P.W. Gray et al.
		U.S. 2004/0110127	06-10-2004	M. Samson et al.
		U.S. 2005/0154193	07-14-2005	V. Roschke et al.
		U.S. 2003/0100058	05-29-2003	V. Roschke et al.
		U.S. 2003/0166024	09-04-2003	C. Rosen et al.
		U.S. 2004/0151719	08-08-2004	Y. Li et al.
		U.S. 2001/0000241	04-12-2002	Y. Li et al.
		U.S. 2001/0046512	11-29-2001	V.M. Litwin et al.
		U.S. 2002/0048786	04-25-2002	C. Rosen et al.
		U.S. 2002/0061834	05-23-2002	C. Rosen et al.
		U.S. 2002/0110870	08-15-2002	M. Samson et al.
		U.S. 2003/0023044	01-30-2003	Y. Li et al.
		U.S. 2006/0029932	02-09-2006	G.P. Allaway et al.
		U.S. 2006/0140977	6-29-2006	G.P. Allaway et al.
		U.S. 2002/0045161	04-18-2002	G.P. Allaway et al.
		U.S. 2004/0062767	04-01-2004	W.C. Olson et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		EP 9687002.1	03-01-1996		
		EP 96870102.9	08-06-1996		
		EP 1145721 A2	10-17-2001		
		EP 1146055 A2	10-17-2001		
		EP 1146122 A2	10-17-2001		
		EP 1148126 A2	10-24-2001		
		EP 1148127 A2	10-24-2001		

EXAMINER
SIGNATURE

DATE CONSIDERED

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

[illegible]

Examiner Initials ⁷	Cite No. ¹	Foreign Patent Document Country Code ² Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		EP 1149582 A2	10-31-2001		
		EP 1199360 A2	04-24-2002		
		EP 1482042 A1	12-01-2004		
		EP 0815137	12-12-1996		
		EP 0883687 B1	11-27-2004		
		CA 2216990	12-27-1997		

DATE CONSIDERED

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Abaza, M.S.I et al., (1992) "Effects Of Amino Acid Substitutions Outside An Antigenic Site On Protein Binding To Monoclonal Antibodies Of Predetermined Specificity Obtained By Peptide Immunization: Demonstration With Region 94-100 (Antigenic Site 3) Of Myoglobin", <i>J. Prot. Chem.</i> 11(5):433-443	
		Alexander, H. et al., (1992) "Altering The Antigenicity Of Proteins", <i>Proc. Natl. Acad. Sci.</i> 89:3352-3356	
		Alkhatib et al., (1996) Abstract At 3rd Conference On Retroviruses	
		Allan, J., (1997) "Human Immunodeficiency Virus-Related Infections In Animal Model Systems", In <i>AIDS: Biology, Diagnosis, Treatment And Prevention</i> , 4th Edition, Lippincott-Raven Publishers, Philadelphia, Pp 15-27	
		Allaway, G.P. et al., (1993) "Synergistic Inhibition Of HIV-1 Envelope-Mediated Cell Fusion By CD4-Based Molecules In Combination With Antibodies To gp120 Or gp41", <i>AIDS Res Hum Retroviruses</i> 9:581-587	
		Allaway, G.P. et al., (1995) "Expression And Characterization Of CD4-IgG ₂ , A Novel Heterotetramer That Neutralizes Primary HIV Type 1 Isolates", <i>AIDS Res Hum Retrovirus</i> 11:533-539	
		Amara, A. et al., (1997) "HIV Coreceptor Downregulation As Antiviral Principle: SDF-1 α -Dependent Internalization Of The Chemokine Receptor CXCR4 Contributes To Inhibition Of HIV Replication", <i>J. Exp. Med.</i> 186:139-146	
		Arthos, J. et al., (1989) "Identification Of The Residues In Human CD4 Critical For The Binding Of HIV". <i>Cell</i> 57:469-481	
		Ashorn, P.A. et al., (1990) "Human Immunodeficiency Virus Envelope Glycoprotein/CD4 Mediated Fusion Of Nonprimate Cells With Human Cells", <i>J. Virol.</i> 64:2149-2156	
		Attanasio, R. et al., (1991) "Anti-Idiotypic Antibody Response To Monoclonal Anti-CD4 Preparations In Nonhuman Primate Species", <i>J. Immunol.</i> 146:507-514	
		Baba, M. et al., (1988) "Mechanism Of Inhibitory Effect Of Dextran Sulfate And Heparin On Replication Of Human Immunodeficiency Virus In Vitro", <i>Proc. Natl. Acad. Sci.</i> 85:6132-6136	
		Baulerle, P.A. And Huttner, W.B., (1987) "Tyrosine Sulfation Is A Trans-Golgi-Specific Protein Modification", <i>Cell. Biol.</i> 105:2655-2663	
		Benet et al. (1990) "Pharmacokinetics: The Dynamics Of Drug Absorption, Distribution And Elimination" In <i>Goodman And Gilman's The Pharmacological Basis Of Therapeutics</i> , Gilman Et El., Eds. Pergamon Press, New York, Pp 3-32	

**EXAMINER
SIGNATURE**
DATE CONSIDERED

^{*}EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Berger, E.A. et al (1996) Abstract No. 002, 8 At Keystone Symposium	
		Berger, E.A., (1997) "HIV Entry And Tropism: The Chemokine Receptor Connection" AIDS 11(Suppl A):S3-S16	
		Berger, E.A. et al., (1999) "Chemokine Receptors As HIV-1 Coreceptors: Roles In Viral Entry, Tropism And Disease", Ann. Rev. Immunol. 17:657-700	
		Bieniasz, P.D. et al., (1997) "HIV-1 Induced Cell Fusion Is Mediated By Multiple Regions Within Both The Viral Envelope And The CCR5 Co-Receptor", EMBO 16:2599-2609	
		Blanpain, C. et al., (1999) "Multiple Charged And Aromatic Residues In CCR5 Amino-Terminal Domain Are Involved In High Affinity Binding Of Both Chemokines And HIV-1 Env Protein", J. Biol. Chem. 274:34719-34727	
		Brelot, A. et al., (1997) "Role Of The First And Third Extracellular Domains Of CXCR4 In Human Immunodeficiency Virus Coreceptor Activity", J. Virol. 71:4744-4751	
		Broder, C.C. et al., (1993) "The Block To HIV-1 Envelope Glycoprotein-Mediated Membrane Fusion In Animal Cells Expressing Human CD4 Can Be Overcome By A Human Cell Component(s)", Virol. 193:483-491	
		Burkly, L. et al., (1995) "Synergistic Inhibition Of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein-Mediated Cell Fusion And Infection By An Antibody To CD4 Domain 2 In Combination With Anti-gp-120 Antibodies", J. Virol. 69:4267-4273	
		Burton, D.R. et al., (1994) "Efficient Neutralization Of Primary Isolates Of HIV-1 By A Recombinant Human Monoclonal Antibody", Science 266:1024-1027	
		Busso, M. et al., (1991) "HIV-Induced Syncytium Formation Requires The Formation Of Conjugates Between Virus-Infected And Uninfected T-Cells In Vitro", AIDS 5:1425-1432	
		Camerini, D. et al., (1990) "A CD4 Domain Important For HIV-Mediated Syncytium Formation Lies Outside The Virus Binding Site", Cell 60:747-754	
		Cammack, N., (1999) "Human Immunodeficiency Virus Type 1 Entry And Chemokine Receptors: A New Therapeutic Target", Antivir. Chem. Chemother. 10:53-62	
		Capon, D.J. et al., (1989) "Designing CD4 Immuno adhesions For AIDS Therapy", Nature 337:525-531	

**EXAMINER
SIGNATURE**

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Chams, V. et al., (1992) "Simple Assay To Screen For Inhibitors Of Interaction Between The Human Immunodeficiency Virus Envelope Glycoprotein And Its Cellular Receptor, CD4", <i>Antimicrob Agents Chemother.</i> 36(2):262-272	
		Chan, D.C. et al., (1998) "Evidence That A Prominent Cavity In The Coiled Coil Of HIV Type 1 gp41 Is An Attractive Drug Target", <i>Proc. Natl. Acad. Sci.</i> 95:15613-15617	
		Chan, D.C. et al., (1998) "HIV Entry And Its Inhibition", <i>Cell</i> 93:681-684	
		Charo, I.F. et al., (1994) "Molecular Cloning And Functional Expression Of Two Monocyte Chemoattractant Protein 1 Receptors Reveals Alternative Splicing Of The Carboxyl-Terminal Tails", <i>Proc. Natl. Acad. Sci.</i> 91:2752-2756	
		Chen, Z. et al., (1997) "Genetically Divergent Strains Of Simian Immunodeficiency Virus Use CCR5 As A Coreceptor For Entry", <i>J. Virol.</i> 71(4):2705-2714	
		Clapham, P.R. et al., (1989) "Soluble CD4 Blocks The Infectivity Of Diverse Strains Of HIV And SIV For T Cells And Monocytes But Not For Brain And Muscle Cells", <i>Nature</i> 337:368-370	
		Clapham, P.R. et al., (1991) "Specific Cell Surface Requirements For The Infection Of CD4-Positive Cells By Human Immunodeficiency Virus Types 1 And 2 By Simian Immunodeficiency Virus", <i>Virol.</i> 181:703-715	
		Co. M.S. et al., (1991) "Humanized Antibodies For Antiviral Therapy" <i>Proc. Natl. Acad. Sci.</i> 88:2869-2873	
		Combadiere, C. et al., (1995) "Cloning And Functional Expression Of A Human Eosinophil CC Chemokine Receptor", <i>J. Biol. Chem.</i> 270:16941-16494	
		Combadiere, C. et al., (1996) "Cloning And Functional Expression Of CC CKR5, A Human Monocyte CC Chemokine Receptor Selective For MIP-1 α , MIP-1 β , And RANTES", <i>J. Leukoc. Biol.</i> 60:147-152	
		Connor, R.I. et al., (1997) "Change In Co-Receptor Use Correlates With Disease Progression In HIV-1 Infected Individuals", <i>J. Exp. Med.</i> 185:621-628	
		Cormier, E. G. et al., (2000) "Specific Interaction Of CCR5 Amino-Terminal Domain Peptides Containing Sulfotyrosines With HIV-1 Envelope Glycoprotein gp120", <i>Proc. Natl. Acad. Sci.</i> 97:5762-5767	

**EXAMINER
SIGNATURE**

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Crowe, S.M. et al., (1992) "Human Immunodeficiency Virus-Infected Monocyte-Derived Macrophages Express Surface gp120 And Fuse With CD4 Lymphoid Cells In Vitro: A Possible Mechanism Of T Lymphocyte Depletion In Vivo", <i>Clin. Immunol Immunopathol.</i> 65(2):143-151	
		Crump, M.P. et al., (1997) "Solution Structure And Basis For Functional Activity Of Stromal-Cell Derived Factor-1: Disassociation Of CXCR4 Activation From Binding And Inhibition Of HIV-1", <i>EMBO</i> 16:6996-7007	
		Cushman, M. et al., (1991) "Preparation And Anti-HIV Activities Of Aurintricarboxylic Acid Fractions And Analogues: Direct Correlation Of Antiviral Potency With Molecular Weight", <i>J. Med. Chem.</i> 34:329-337	
		Dalgleish, A.G. et al., (1984) "The CD4 (T4) Antigen Is An Essential Component Of The Receptor For The AIDS Retrovirus" <i>Nature</i> 312:763-766	
		Dalgleish, A.G., (1995) "HIV And CD26", <i>Nat. Med.</i> 1:881-882	
		De Rossi, A. et al., (1995) "Synthetic Peptides From The Principle Neutralizing Domain Of Human Immunodeficiency Virus Type 1 (HIV-1) Enhance HIV-1 Infection Through A CD4-Dependent Mechanism", <i>Virology</i> 184:187-196	
		Dean, M. et al., (1996) "Genetic Restriction Of HIV-1 Infection And Progression To AIDS By A Deletion Allele Of The CCR5 Structural Gene", <i>Science</i> 273:1856-1862	
		Deen, K.C. et al., (1988) "A Soluble Form Of CD4(T4) Protein Inhibits AIDS Virus Infection", <i>Nature</i> 331:82-84	
		Deng, X. et al., (1999) "A Synthetic Peptide Derived From Human Immunodeficiency Virus Type 1 gp120 Downregulates The Expression And Function Of Chemokine Receptors CCR5 And CXCR4 In Monocytes By Activating The 7-Transmembrane G-Protein-Coupled Receptor FPRL1/LXA4R", <i>Blood</i> 94(4):1165-1173	
		Dettin, M. et al., (2003) "CCR5 N-Terminus Peptides Enhance X4 HIV-1 Infection By CXCR4 Up-Regulation", <i>Biochem. Biophys. Res. Commun.</i> 307(3):640-646	
		Dimitrov, D.S. et al., (1991) "Initial Stages Of HIV-1 Envelope Glycoprotein-Mediated Cell Fusion Monitored By A New Assay Based On Redistribution Of Fluorescent Dyes", <i>AIDS Res Hum Retroviruses</i> 7(10):799-805	
		Ditzel, H.J. et al., (1998) "The CCR5 Receptor Acts As An Alloantigen In CCR5Δ32 Homozygous Individuals: Identification Of Chemokine And HIV-1 Blocking Human Antibodies", <i>Proc. Natl. Acad. Sci.</i> 95(9):5241-5245	

**EXAMINER
SIGNATURE**
DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Donzella, G.A. et al., (1998) "AMD3100, A Small Molecule Inhibitor Of HIV-1 Entry Via The CXCR4 Co-Receptor", <i>Nat. Med.</i> 4:72-77	
		Doranz, B.J. et al., (1997) "Two Distinct CCR5 Domains Can Mediate Co-Receptor Usage By Human Immunodeficiency Virus Type 1", <i>J. Virol.</i> 71:6305-6314	
		Dragic, T. et al., (1992) "Complementation Of Murine Cells For Human Immunodeficiency Virus Envelope/CD4-Mediated Fusion In Human/Murine Heterokaryons", <i>J. Virol.</i> 66(8):4794-4802	
		Dragic, T.V. et al., (1993) "Different Requirements For Membrane Fusion Mediated By The Envelopes Of Human Immunodeficiency Virus Types 1 And 2", <i>J. Virol.</i> 67(4):2355-2359	
		Dragic, T.V. et al., (1995) "Proteinase-Resistant Factors In Human Erythrocyte Membranes Mediate CD-4 Dependent Fusion With Cells Expressing Human Immunodeficiency Virus Type 1 Envelope Glycoproteins", <i>J. Virol.</i> 69:1013-1018	
		Dragic, T.V. et al., (1998) "Amino-Terminal Substitutions In The CCR5 Coreceptor Impair gp120 Binding And Human Immunodeficiency Virus Type 1 Entry" <i>J. Virol.</i> 72(1):279-285	
		Dragic, T.V. et al., (2000) "A Binding Pocket For A Small Molecule Inhibitor Of HIV-1 Entry Within The Transmembrane Helices Of CCR5", <i>Proc. Natl. Acad. Sci.</i> 97(10):5639-5644	
		Ebadi, M., (1998) "The Pharmacokinetic Basis Of Therapeutics", In CRC Desk Reference Of Clinical Pharmacology, CRC Press LLC, Boca Raton, Pp. 1-7	
		Eckert, D.M. et al., (1999) "Inhibiting HIV-1 Entry: Discovery Of D-Peptide Inhibitors That Target The gp41 Coiled-Coil Pocket", <i>Cell</i> 99:103-115	
		Eugene-Olsen, J. et al., (1997) "Heterozygosity For A Deletion In The CKR-5 Gene Leads To Prolonged AIDS-Free Survival And Slower CD4 T-Cell Decline In A Cohort Of HIV-Seropositive Individuals", <i>AIDS</i> 11:305-310	
		Farzan, M. et al., (1998) "A Tyrosine-Rich Region In The N-Terminus Of CCR5 Is Important For Human Immunodeficiency Virus Type 1 Entry And Mediates Association Between gp120 And CCR5", <i>J. Virol.</i> 72:1160-1164	
		Farzan, M. et al., (1999) "Tyrosine Sulfation Of The Amino-Terminus Of CCR5 Facilitates HIV-1 Entry", <i>Cell</i> 96:667-676	
		Farzan, M. et al., (2000) "A Tyrosine-Sulfated Peptide Based On The N Terminus Of CCR5 Interacts With A CD4-Enhanced Epitope Of The HIV-1 gp 120 Envelope Glycoprotein And Inhibits HIV-1 Entry", <i>J. Biol. Chem.</i> 275:33416-33521	

EXAMINER SIGNATURE	DATE CONSIDERED
<p><small>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.</small></p>	

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Feng, Y. et al., (1996) Abstract No. 116,21 At Keystone Symposium	
		Ferrer, M. et al., (1999) "Selection Of gp-41 Mediated HIV-1 Cell Entry Inhibitors From Biased Combinatorial Libraries Of Non-Natural Binding Elements", <i>Nature Struct. Biol.</i> 6:953-959	
		Fouchier, R.A. et al., (1994) "HIV-1 Macrophage Tropism Is Determined At Multiple Levels Of The Viral Replication Cycle", <i>J. Clin. Invest.</i> 94:1806-1814	
		Fouts, T.R. et al., (1997) "Neutralization Of The Human Immunodeficiency Virus Type 1 Primary Isolate JR-FL By Human Monoclonal Antibodies Correlates With Antibody Binding To The Oligomeric Form Of The Envelope Glycoprotein Complex", <i>J. Virol.</i> 71:2779-2785	
		Freed, E.O. et al., (1991) "Identification Of Conserved Residues In The Human Immunodeficiency Virus Type 1 Principal Neutralizing Determinant That Are Involved In Fusion", <i>AIDS Res. Hum. Retroviruses</i> 7(10):807-811	
		Fradd, F. and Mary, M.E. (1989) "AIDS Vaccines: An Investor's Guide By Shearman Lehman Hutton", Page 10 (Fig. 2)	
		Frazer, J.K. and Capra, J.D., (1999) "Immunoglobulins: Structure And Function" Fundamental Immunology, 4th Edition, Lippincott-Raven Publishers, Philadelphia, Pp. 37-74	
		Furuta, R.A. et al., (1998) "Capture Of An Early Fusion-Active Conformation Of HIV-1 gp41", <i>Nature Struct. Biol.</i> 5(4):276-279	
		Gauduin, M.C. et al., (1996) "Effective Ex Vivo Neutralization Of Human Immunodeficiency Virus Type 1 in Plasma By Recombinant Immunoglobulin Molecules", <i>J. Virol.</i> 70:2586-2592	
		Gauduin, M.C. et al., (1997) "Passive Immunization With A Human Monoclonal Antibody Protects hu-PBL-SCID Mice Against Challenge By Primary Isolates Of HIV-1", <i>Nat. Med.</i> 3:1389-1393	
		Ghorpade, A. et al, (1998) "Role Of The β -Chemokine Receptors CCR3 And CCR5 In Human Immunodeficiency Virus Type 1 Infection Of Monocytes And Microglia", <i>J. Virol.</i> 72:3351-3361	
		Golding, H. et al., (1992) "LFA-1 Adhesion Molecules Are Not Involved In The Early Stages Of HIV-1 env-Mediated Cell Membrane Fusion", <i>AIDS Res. Hum. Retroviruses</i> 8:1593-1598	
		Graham, B.S. et al., (1995) "Candidate AIDS Vaccines", <i>New Engl. J. Med.</i> 333:1331-1339	

**EXAMINER
SIGNATURE**
DATE CONSIDERED

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Greene, E. et al., (2001) "Anti-CCR5 Antibodies In Sera Of HIV-Positive Individuals", <i>Human Immunol.</i> 62(2):143-145	
		Harouse, J.M. et al., (1991) "Inhibition Of Entry Of HIV-1 In Neural Cell Lines By Antibodies Against Galactosyl Ceramide", <i>Science</i> , 253:320-323	
		Harrington, R.D. And Geballe, A.P., (1993) "Cofactor Requirement For Human Immunodeficiency Virus Type 1 Entry Into A CD4-Expressing Human Cell Line", <i>J. Virol</i> 67:5939-5947	
		He, J. et al., (1997) "CCR3 And CCR5 Are Co-Receptors For HIV-1 Infection Of Microglia", <i>Nature</i> 385: 645-649	
		Heath, et al., (1997) "Chemokine Receptor Usage By Human Eosinophils. The Importance Of CCR3 Demonstrated Using An Antagonistic Monoclonal Antibody", <i>J. Clin. Invest.</i> 99:178-184	
		Heidenreich, O. et al., (1995) "Application Of Antisense Technology To Therapeutics", <i>Mol. Med. Today</i> 1:128-133	
		Hildreth, J.E. et al., (1989) "Involvement Of A Leukocyte Adhesion Receptor (LFA-1) In HIV-Induced Syncytium Formation" <i>Science</i> 244:1075-1078	
		Hill, C.M. et al., (1998) "The Amino Terminus Of Human CCR5 Is Required For Its Function As A Receptor For Diverse Human And Simian Immunodeficiency Virus Envelope Glycoproteins", <i>Virology</i> 248:357-371	
		Hirata, Y., (1989) "Characterization Of IL-6 Receptor Expression By Monoclonal And Polyclonal Antibodies", <i>J. Immun.</i> 143(9):2900-2906	
		Hirsch, M.S. et al., (1997) "Antiretroviral Therapy" In <i>AIDS: Biology, Diagnosis, Treatment, And Prevention</i> , 4th Edition, Lippincott-Raven Publishers, Philadelphia, Pp. 495-508	
		Hwang, S. et al., (1991) "Identification Of The Envelope V3 Loop As The Primary Determinant Of Cell Tropism In HIV-1," <i>Science</i> 253:71-74	
		Jacobson, J.M. et al., (1993) "Passive Immunotherapy In The Treatment Of Advanced Human Immunodeficiency Virus Infection", <i>J. Infect. Dis.</i> 168:298-305	
		Jacobson, J. et al., (1999) "Results Of A Phase I Trial Of Single-Dose PRO 542, A Novel Inhibitor Of HIV Entry", Abstracts Of The 39th Interscience Conference On Antimicrobial Agents And Chemotherapy 14	
		Ji, H. et al., (1999) "Inhibition Of Human Immunodeficiency Virus Type 1 Infectivity By The gp41 Core: Role Of A Conserved Hydrophobic Cavity In Membrane Fusion", <i>J. Virol</i> 73:8578-8586	

**EXAMINER
SIGNATURE**

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Jiang, S. et al., (1993) "HIV-1 Inhibition By A Peptide", <i>Nature</i> 365: 113	
		Karwowska, S. et al., (1991) "Passive Immunization For The Treatment And Prevention Of HIV Infection", <i>Biotech. Therap.</i> 2:31-48	
		Katinger, H., (1994) "Human Monoclonal Antibodies For Passive Immunotherapy Of HIV-1" <i>Antibiot. Chemother.</i> 46:25-37	
		Keller, P.M. et al., (1977) "A Fluorescence Enhancement Assay Of Cell Fusion" <i>J. Cell Sci.</i> 28:167-177	
		Kilby, J.M. et al., (1998) "Potent Suppression Of HIV-1 Replication In Humans By T-20, A Peptide Inhibitor Of gp41-Mediated Virus Entry", <i>Nat. Med.</i> 4:1302-1307	
		Konigs, C. et al. (2000) "Monoclonal Antibody Screening Of Phage-Displayed Random Peptide Library Reveals Mimotopes Of Chemokine Receptor CCR5: Implications For The Tertiary Structure Of The Receptor And For An N-Terminal Binding Site For HIV-1 gp120", <i>Eur. J. Immunol.</i> 30(4):1162-1171	
		Konishi, K. et al., (2000) "Synthesis Of Peptides Mimicking Chemokine Receptor CCR5 And Their Inhibitory Effects Against HIV-1 Infection", <i>Chem. Pharm. Bull</i> (Tokyo) 48(2):308-309	
		Koup, R.A. et al., (1996) "Defining Antibody Protection Against HIV-1 Transmission In Hu-PBL-SCID Mice", <i>Immunology.</i> 8:263-268	
		Kwong P.D. et al., (1998) "Structure Of An HIV gp120 Envelope Glycoprotein In Complex With The CD4 Receptor And Neutralizing Human Antibody", <i>Nature</i> 393:648-659	
		Laal, S. et al., (1994) "Synergistic Neutralization Of Human Immunodeficiency Virus Type 1 By Combinations Of Human Monoclonal Antibodies", <i>J. Virol</i> 68:4001-4008	
		Lacasse, R.A. et al., (1999) "Fusion-Competent Vaccines: Broad Neutralization Of Primary Isolates Of HIV", <i>Science</i> 283:357-362	
		Lee, B. et al., (1999) "Epitope Mapping Of CCR5 Reveals Multiple Conformational States And Distinct But Overlapping Structures Involved In Chemokine Coreceptor Function", <i>J. Biol. Chem.</i> 274:9617-9626	
		Lehner, T. et al., (2001) "Immunogenicity Of The Extracellular Domains Of C-C Chemokine Receptor 5 And The In Vitro Effects On Simian Immunodeficiency Or HIV Infectivity", <i>J. Immunol.</i> 166(12):7446-7455	
		Li, A. et al., (1997) "Synergistic Neutralization Of A Chimeric SIV/HIV Type 1 Virus With Combinations Of Human Anti-HIV Type 1 Envelope Monoclonal Antibodies Or Hyperimmune Globulins", <i>AIDS Res. Hum. Retroviruses</i> 13:647-56	

**EXAMINER
SIGNATURE**

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Li, A.H. et al., (1998) "Synergistic Neutralization Of Simian-Human Immunodeficiency Virus SHIV-Vpu+ By Triple And Quadruple Combination Of Human Monoclonal Antibodies And High-Titer Antihuman Immunodeficiency Virus Type 1 Immunoglobulins", <i>J. Virol.</i> 72:3235-3240	
		Mack, M. et al., (1998) "Aminooxypentane-RANTES Induces CCR5 Internalization But Inhibits Recycling: A Novel Inhibitory Mechanisms Of HIV Infectivity", <i>J. Exp. Med.</i> 187:1215-1224	
		Mackay, C.R., (1996) "Chemokine Receptors And T Cell Chemotaxis", <i>J. Exp. Med.</i> 84: 799-802	
		Maddon, P.J. et al., (1986) "The T4 Gene Encodes The AIDS Virus Receptor And Is Expressed In The Immune System And The Brain", <i>Cell</i> 47:333-348	
		Markosyan, R.M. et al., (2002) "The Mechanism Of Inhibition Of HIV-1 Entry Env-Mediated Cell-Cell Fusion By Recombinant Cores Of gp41 Ectodomain", <i>Virology</i> 302:174-184	
		Mateu, M.G. et al. (1992) "Non-Additive Effects Of Multiple Amino Acid Substitutions On Antigen-Antibody Recognition", <i>European J. Immunol.</i> 22(6):1385-1389	
		Max, E., "Immunoglobulins: Molecular Genetics" Fundamental Immunology, 4th Edition. Lippincott-Raven Publishers, Philadelphia, 1999 Pp. 11-182	
		Mitsuya, H. et al., (1985) "Protection Of T Cells Against Infectivity And Cytopathic Effect Of HTLV-III In Vitro", <i>Retroviruses In Human Lymphoma Leukemia Japan Sci. Soc. Press, Tokyo/VNU Science Press, Utrecht</i> Pp.277-288	
		Mittler, R.S. et al. (1989) "Synergism Between HIV gp120 And gp120-Specific Antibody In Blocking Human T. Cell Activation", <i>Science</i> 245:1380-1382	
		Mohan, P. et al., (1992) "Sulfonic Acid Polymers As A New Class Of Human Immunodeficiency Virus Inhibitors", <i>Antiviral Res.</i> 18:139-150	
		Mosier, D.E., (1990) "Immunodeficient Mice Xenografted With Human Lymphoid Cells: New Models For In-Vivo Studies Of Human Immunobiology And Infectious Diseases", <i>J. Clin. Immunol.</i> 10(4):185-191	
		Nagasawa, T. et al., (1994) "Molecular Cloning And Structure Of A Pre-B-Cell Growth-Stimulating Factor", <i>Proc. Natl. Acad. Sci.</i> 91:2305-2309	
		Nagashima, K.A. et al., (2001) "Human Immunodeficiency Virus Type 1 Entry Inhibitors PRO 542 And T-20 Are Potently Synergistic In Blocking Virus-Cell And Cell-Cell Fusion", <i>J. Infect. Dis.</i> 183:1121-1125	

EXAMINER SIGNATURE	DATE CONSIDERED
--------------------	-----------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Nakano, T. et al., (1995) "Vascular Smooth Muscle Cell-Derived, Gla-Containing Growth-Potentiating Factor For Ca(2+)-Mobilizing Growth Factors", <i>J. Biol. Chem.</i> 270(11):5702-5705	
		Neote, K. et al., (1993) "Molecular Cloning, Functional Expression, And Signaling Characteristics Of A C-C Chemokine Receptor", <i>Cell</i> 72:415-425	
		O'Brien, W.A. et al., (1990) "HIV-1 Tropism For Mononuclear Phagocytes Can Be Determined By Regions Of gp120 Outside Of The CD4-Binding Domain", <i>Nature</i> 348:69-73	
		Olson, W.C. et al., (1999) "Differential Inhibition Of Human Immunodeficiency Virus Type 1 Fusion, gp 120 Binding And CC-Chemokine Activity Of Monoclonal Antibodies To CCR5", <i>J. Virol.</i> 73:4145-4155	
		Oppermann, M. (2004) "Chemokine Receptor CCR5: Insights Into Structure, Function, And Regulation", <i>Cell. Signal.</i> 16:1201-1210	
		Parren, P.W. et al., (2001) "Antibody Protects Macaques Against Vaginal Challenge With A Pathogenic R5 Simian/Human Immunodeficiency Virus At Serum Levels Giving Complete Neutralization In Vitro" <i>J. Virol.</i> 75:8340-8347	
		Partidos, C. et al., (1992) "The Effect Of Orientation Of Epitopes On The Immunogenicity Of Chimeric Synthetic Peptides Representing Measles Virus Protein Sequences", <i>Molecular Immunology</i> 29(5):651-658	
		Peden, K. et al., (1991) "Changes In Growth Properties On Passage In Tissue Culture Of Viruses Derived From Infectious Molecular Clones Of HIV-1LAI, HIV-1MAL, And HIV-1ELI", <i>Virol.</i> 185:661-672	
		Poignard, P. et al., (1999) "Neutralizing Antibodies Have Limited Effects On The Control Of Established HIV-1 Infection In Vivo", <i>Immunity</i> 10:431-438	
		Posner, M.R. et al., (1993) "Neutralization Of HIV-1 By F105, A Human Monoclonal Antibody To The CD4 Binding Site Of gp120", <i>J. Acq. Immune Defic. Synd.</i> 6:7-14	
		Power, C.A. et al., (1995) "Molecular Cloning And Functional Expression Of A Novel CC Chemokine Receptor cDNA From A Human Basophilic Cell Line", <i>J. Biol. Chem.</i> 270:19495-19500	
		Proudfoot, A.E. et al., (1996) "Extension Of Recombinant Human RANTES By The Retention Of The Initiating Methionine Produces A Potent Antagonist", <i>J. Biol. Chem.</i> 271:2599-2603	
		Queen, C. et al., (1989) "A Humanized Antibody That Binds To The Interleukin 2 Receptor", <i>Proc. Natl. Acad. Sci</i> 86:10029-10033	

EXAMINER SIGNATURE	DATE CONSIDERED
-------------------------------	------------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Rabut, G.E. et al., (1991) "Alanine Substitutions Of Polar And Nonpolar Residues In The Amino-Terminal Domain Of CCR5 Differently Impair Entry Of Macrophage And Dualtropic Isolates Of Human Immunodeficiency Virus Type 1", <i>J. Virol.</i> 72:3464-3468	
		Raport, C.J. et al., (1996) "Molecular Cloning And Functional Characterization Of A Novel Human CC-Chemokine Receptor (CCR5) For RANTES, MIP-1 β , And MIP-1 α ", <i>J. Biol. Chem.</i> 271:1761-17166	
		Rodriguez, G. et al (1995) "Mediation Of Human Immunodeficiency Virus Type 1 Binding By Interaction Of Cell Surface Heparin Sulfate Proteoglycans With V3 Region Of Envelope gp120-gp41", <i>J. Virol.</i> 69:2233-2239	
		Rucker, J. et al., (1996) "Regions In B-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity", <i>Cell</i> 87:437-446	
		Ruffing, N. et al., (1998) "CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells", <i>Cell. Immunol.</i> 189:160-168	
		Rudikoff, S. et al., (1982) "Single Amino Acid Substitution Altering Antigen-Binding Specificity", <i>Proc. Natl. Acad. Sci.</i> 79:1979-1983	
		Rusche, J.R. et al., (1988) "Antibodies That Inhibit Fusion Of Human Immunodeficiency Virus-Infected Cells Bind A 24-Amino Acid Sequence Of The Viral Envelope gp120", <i>Proc. Natl. Acad. Sci.</i> 85:3198-3202	
		Sagg, M. (1997) "Clinical Spectrum Of Human Immunodeficiency Virus Diseases" <i>AIDS: Biology, Diagnosis, Treatment And Prevention</i> , Lippincott-Raven Publishers, Philadelphia, Pp. 203-213	
		Sandberg, J. and Slikker, W., (1995) "Developmental Pharmacology And Toxicology Of Anti-HIV Therapeutic Agents: Dideoxynucleosides", <i>FASEB J.</i> 9:1157-1163	
		Sandstorm, E.G. And Kaplan, J.C., (1987) "Antiviral Therapy In AIDS: Clinical Pharmacological Properties And Therapeutic Experience To Date", <i>Drugs</i> 34:372-390	
		Sato, A.I. et al., (1992) "Anti-CD7 Reagents Inhibit HIV-1 Induced Syncytium Formation," <i>International Conference On AIDS.</i> 81. PA5 Poa 2017	
		Sato, A.I. et al., (1994) "Identification Of CD7 Glycoprotein As An Accessory Molecule In HIV-1 Mediated Syncytium Formation And Cell Free Infection", <i>J. Immunol.</i> 152:5142-5152	
		Sato, A.I. et al., (1995) "A Simple And Rapid Method For Preliminary Evaluation Of In Vivo Efficacy Of Anti-HIV Compounds In Mice", <i>Antivir. Res.</i> 27:151-163	

**EXAMINER
SIGNATURE**

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Schanberg, L.W. et al., (1995) "Characterization Of Human CD7 Transgenic Mice", <i>J. Of Immunol.</i> 155: 2407-2418	
		Schmidtayerova, H. et al., (1993) "Characterization Of HIV1-PAR, A Macrophage-Tropic Strain: Cell Tropism, Virus/Cell Entry And Nucleotide Sequence Of The Envelope Glycoprotein. <i>Research In Virology</i> 144(1):21-26	
		Schols, D. et al., (1990) "Dextran Sulfate And Other Olyanionic Anti-HIV Compounds Specifically Interact With The Viral gp120 Glycoprotein Expressed By T-Cells Persistently Infected With HIV-1", <i>Virol.</i> 175:556-561	
		Schols, D. et al., (1991) "Selective Inhibitory Activity Of Polyhydroxycarboxylates Derived From Phenolic Compounds Against Human Immunodeficiency Virus Replication", <i>J. Acq. Immune Defic. Synd.</i> 4:677-685	
		Schols, D. et al., (1999) "CD26-Processed RANTES(3-68), But Not Intact RANTES, Has Potent Anti-HIV-1 Activity", <i>Antiviral Res.</i> 30:175-187	
		Sinangil, F. et al., (1988) "Quantitative Measurement Of Fusion Between Human Immunodeficiency Virus And Cultured Cells Using Membrane Fluorescence Dequenching", <i>FEB</i> 239(1):88-92	
		Sommerfelt, M.A. et al., (1995) "Intercellular Adhesion Molecule 3, A Candidate Human Immunodeficiency Virus Type 1 Co-Receptor On Lymphoid And Monocytoid Cells", <i>J. Gen. Virol.</i> 76:1345-1352	
		Stein, D.S. et al., (1993) "Immune-Based Therapeutics: Scientific Rationale And Promising Approaches To The Treatment Of The Human Immunodeficiency Virus-Infected Individual", <i>Clin. Infect. Dis.</i> 17:749-771	
		Steinberger, P. et al., (2000) "Generation And Characterization Of A Recombinant Human CCR5-Specific Antibody", <i>J. Biol. Chem.</i> 275:36073-36078	
		Stewart, G.J., (1997) "Increased Frequency Of CCR-5 Δ32 Heterozygotes Among Long-Term Non-Progressors With HIV-1 Infection", <i>AIDS</i> 11:1833-1838	
		Strizki, J.M. et al., (1997) "A Monoclonal Antibody (12G5) Directed Against CXCR4 Inhibits Infection With The Dual-Tropic Human Immunodeficiency Virus Type 1 Isolates HIV-1 89.6 But Not The T-Tropic Isolate HIV-1 Hxb", <i>J. Virol.</i> 71:5678-5683	
		Su, S.B. et al., (1996) "Preparation Of Specific Polyclonal Antibodies To A C-C Chemokine Receptor, CCR1, And Determination Of CCR1 Expression On Various Types Of Leukocytes" <i>J. Leukoc. Biol.</i> 60:658-666	
		Szabo, G. Jr. et al., (1993) "Specific Disengagement Of Cell-Bound Anti-LAM-1 (Anti-Selectin) Antibodies By Aurintricarboxylic Acid," <i>Molecular Immunology</i> 30(18):1689-1694	

EXAMINER SIGNATURE	DATE CONSIDERED
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.</p>	

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Thali, M. et al., (1992) "Cooperativity Of Neutralizing Antibodies Directed Against The VS And CD4 Binding Regions Of The Human Immunodeficiency Virus gp120 Envelope Glycoprotein", <i>J. Acq. Immun. Defic. Synd.</i> 5:591-599	
		Tilley, S. A. (1992) "Synergistic Neutralization Of HIV-1 By Human Monoclonal Antibodies Against The V3 Loop And The CD4-Binding Site gp120", <i>AIDS Research And Human Retroviruses</i> 80:4:461-467	
		Tilley, S. A. et al., (1991) "Potent Neutralization Of HIV-1 By Human And Chimpanzee Monoclonal Antibodies Directed Against Three Distinct Epitope Clusters Of gp120", <i>Sixieme Colloque Des Cent Gardes.</i> 211-216	
		Travis, B.M. et al., (1992) "Functional Roles Of The V3 Hypervariable Region Of HIV-1 gp160 In The Processing Of gp160 And In The Formation Of Syncytia In CD4-Positive Cells", <i>Virol.</i> 186:313-317	
		Tremblay, C.L. et al. (2000) "Strong In Vitro Synergy Observed Between The Fusion Inhibitor T-20 And A CXCR4 Blocker AMD-3100.", 7th Conference On Retroviruses And Opportunistic Infections Abstract 500	
		Tremblay, C.L. et al., (1999) "Strong In Vitro Synergy Between The Fusion Inhibitor T-20 And The CXCR4 Blocker AMD-3100", <i>J. Acq. Immun. Defici. Synd.</i> 25(2)99-102	
		Trkola, A. et al., (2001) "Potent, Broad-Spectrum Inhibition Of Human Immunodeficiency Virus Type 1 By The CCR5 Monoclonal Antibody PRO 140", <i>J. Virol.</i> 75:579-588	
		Trkola, A et al (1999) "Cross-Clade Neutralization Of Primary Isolates Of Human Immunodeficiency Virus Type 1 By Human Monoclonal Antibodies And Tetrameric CD4-IgG", <i>J. Virol.</i> 69:6609-6617	
		Trkola, A. et al., (1998) "Neutralization Sensitivity Of Human Immunodeficiency Virus Type 1 Primary Isolates To Antibodies And CD4-based Reagents Is Independent Of Coreceptor Usage", <i>J. Virol.</i> 72:1876-1885	
		Tulip, W.R. et al., (1992) "Crystal Structures Of Two Mutant NERAMINIDASE-Antibody Complexes With Amino Acid Substitutions In The Interface", <i>J. Mol. Biol.</i> 227:149-159	
		Valentin, A. et al., (1990) "The Leukocyte Adhesion Glycoprotein CD18 Participates In HIV Induced Syncytia Formation In Monocytoid And T Cells", <i>J. Immunol.</i> 144:934-937	
		Valenzuela, A. et al., (1997) "Neutralizing Antibodies Against The V3 Loop Of Human Immunodeficiency Virus Type 1 Block The CD4-Dependent And Independent Binding Of Virus To Cells", <i>J. Virol.</i> 71(11):8289-8298	
		Vanini, S. et al., (1992) "Discrete Regions Of HIV-1 gp41 Defined By Syncytia-Inhibiting Affinity-Purified Human Antibodies", <i>AIDS</i> 7:167-174	

**EXAMINER
SIGNATURE**
DATE CONSIDERED

¹EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Verrier, F.C. et al., (1997) "Antibodies To Several Conformation-Dependent Epitopes Of gp120/gp41 Inhibit CCR-5-Dependent Cell-To-Cell Fusion Mediated By The Native Envelope Glycoprotein Of A Primary Macrophage-Tropic HIV-1 Isolate", <i>Proc. Natl. Acad. Sci.</i> 94:9326-9331	
		Vijh-Warrier, S, (1996) "Synergistic Neutralization Of Human Immunodeficiency Virus Type 1 By A Chimpanzee Monoclonal Antibody Against The V2 Domain Of gp120 In Combination With Monoclonal Antibodies Against The V3 Loop And The CD4-Binding Site", <i>J. Virol.</i> 70:4466-4473	
		Vila-Coro, A.J. et al., (2000) "HIV-1 Infection Through The CCR5 Receptor Is Blocked By Receptor Dimerization", <i>Proc. Natl. Acad. Sci.</i> 97(7):3388-3393	
		Vita, C. et al., (1999) "Rational Engineering Of A Miniprotein That Reproduces The Core Of The CD4 Site Interacting With HIV-1 Envelope Glycoprotein", <i>Proc. Natl. Acad. Sci.</i> 96:13091-13096	
		Wang, Z.Q. et al., (1994) "Deletion Of T Lymphocytes In Human CD4 Transgenic Mice Induced By HIV-gp120 And gp120-Specific Antibodies From AIDS Patients", <i>Eur. J. Immunol.</i> 24:1553-1557	
		Wanda, P.E., And Smith, J.D., (1982) "A General Method For Heterokaryon Detection Using Resonance Energy Transfer And A Fluorescence-Activated Cell Sorter", <i>J. Histochem. & Cytochem.</i> 30(12):1297-1300	
		Weinhold, K.J., et al., (1989) "HIV-1 gp120-Mediated Immune Suppression And Lymphocyte Destruction In The Absence Of Viral Infection", <i>J. Immunol.</i> 142:3091-3097	
		Wild, C. et al., (1992) "A Synthetic Peptide Inhibitor Of Human Immunodeficiency Virus Replication: Correlation Between Solution Structure And Viral Inhibition", <i>Proc. Natl. Acad. Sci.</i> 89:10537-10541	
		Wild, C. et al., (1993) "A Synthetic Peptide From HIV-1 gp41 Is A Potent Inhibitor Of Virus Mediated Cell-Cell Fusion", <i>AIDS Res. Hum. Retroviruses</i> 9:1051-1053	
		Wild, C. et al., (1994) "Peptides Corresponding To A Predictive Alpha-Helical Domain Of Human Immunodeficiency Virus Type 1 gp41 Are Potent Inhibitors Of Virus Infection", <i>Proc. Natl. Acad. Sci.</i> 91:9770-9774	
		Wild, C. et al., (1995) "The Inhibitory Activity Of An HIV Type 1 Peptide Correlates With Its Ability To Interact With A Leucine Zipper Structure", <i>AIDS Res. Hum. Retroviruses</i> 11:323-325	

**EXAMINER
SIGNATURE**

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.



PTO/SB/08A (04-07)

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1

of 29

Complete if Known

Application Number	09/460,216
Filing Date	December 13, 1999
First Named Inventor	G.P. Allaway et al.
Art Unit	1648
Examiner Name	Jeffrey S. Parkin
Attorney Docket Number	50875-F-PCT-US

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 6,692,745	02-17-2004	Olson	
		US- 6,797,811	09-28-2004	Gray	
		US- 5,126,433	12-21-1989	Maddon	
		US- 5,021,409	06-04-1991	Murrer	
		US- 5,440,021	08-05-1995	Chuntharapai	
		US- 5,504,003	04-02-1996	Haodong Li	
		US- 7,118,859	10-10-2006	V.M. Litwin et al.	
		US- 7,138,119	11-21-2006	W.C. Olson et al.	
		US- 7,060,273	06-13-2006	W.C. Olson et al.	
		US- 7,122,185	10-17-2006	W.C. Olson et al.	
		US- 6,908,734	06-21-2005	T. Dragic et al.	
		US- 2003-0166870	12-23-2004	L. Wu et al.	
		US- 2005-0118677	06-02-2005	C. Combadiere et al.	
		US- 2007-0031408 A1	02-08-2007	W.C. Olson et al.	
		US- 2007-0020280 A1	01-25-2007	W.C. Olson et al.	
		US- 2007-0025983 A1	02-01-2007	V.M. Litwin et al.	
		US- 2007-0026441 A1	02-01-2007	W.C. Olson et al.	
		US- 11/581,944	10-16-2006	W.C. Olson et al.	
		US- 2006-0194244	08-31-2006	G.P. Allaway et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		WO 07/014114	02-01-2007			
		WO 94/22477	10-13-1994			

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicants: G.P. Allaway, et al.
Serial No.: 09/460,216
Filed: December 13, 1999
Exhibit B

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2

of 29

Complete if Known

Application Number	09/460,216
--------------------	------------

Filing Date	December 13, 1999
-------------	-------------------

First Named Inventor	G.P. Allaway et al.
----------------------	---------------------

Art Unit	1648
----------	------

Examiner Name	Jeffrey S. Parkin
---------------	-------------------

Attorney Docket Number	50875-F-PCT-US
------------------------	----------------

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/460,216		
		Filing Date	December 13, 1999		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffrey S. Parkin		
Sheet	3	of	29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PCT International Preliminary Examination Report issued October 18, 1996 for International Application Publication No. WO 95/16789	
		PCT International Preliminary Examination Report issued September 5, 1997 for International Application Publication No. WO 96/41020	
		PCT International Preliminary Examination Report issued October 16, 1999 for International Application Publication No. WO 97/47319	
		PCT International Preliminary Examination Report issued September 28, 2005 for International Application Publication No. WO 03/072766	
		PCT International Preliminary Examination Report issued February 15, 2001 for International Application Publication No. WO 00/35409	
		PCT International Preliminary Examination Report issued December 24, 2003 for International Application Publication No. WO 02/083172	
		PCT International Search Report issued March 13, 1995 for International Application Publication No. WO 95/16789	
		PCT International Search Report issued October 10, 1996 for International Application Publication No. WO 96/41020	
		PCT International Search Report issued June 9, 1997 for International Application Publication No. WO 97/26009	
		PCT International Search Report issued September 3, 1997 for International Application Publication No. WO 97/47319	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number		09/460,216
	Filing Date		December 13, 1999
	First Named Inventor		G.P. Allaway
	Art Unit		1648
	Examiner Name		Jeffrey S. Parkin
	Attorney Docket Number		50875-F-PCT-US

Sheet

4

of

29

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PCT International Search Report issued September 3, 1997 for International Application Publication No. WO 97/47318	
		PCT International Search Report issued June 7, 2000 for International Application Publication No. WO 00/35409	
		PCT International Search Report issued August 13, 2003 for International Application Publication No. WO 03/072766	
		PCT International Search Report issued April 23, 2002 for International Application Publication No. WO 02/22077	
		PCT International Search Report issued July 31, 2003 for International Application Publication No. WO 02/083172	
		PCT International Preliminary Examination Report issued April 5, 2006 for International Application Publication No. WO 03/072766	
		PCT Written Opinion issued May 25, 2005 in connection with International Application Publication No. WO 03/072766	
		European Supplementary Search Report issued February 24, 2000 for European Patent Application No. 96921473.3	
		European Supplementary Search Report issued September 5, 2002 for European Patent Application No. 95905987.4	
		European Supplementary Search Report issued April 27, 2006 for European Patent Application No. 01970984.9	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet 5 of 29	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	G.P. Allaway
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
Attorney Docket Number		50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		European Supplementary Search Report issued April 21, 2006 for European Application No. 03713632.2	
		European Supplementary Partial Search Report issued August 26, 2004 for European Patent Application No. 97930120.7	
		European Supplementary Partial Search Report issued November 8, 2004 for European Patent Application No. 97930120.7	
		European Supplementary Partial Search Report issued September 27, 2004 for European Application No. 99966466	
		European Patent Office Communication issued November 11, 2004 in connection with European Patent Application No. 97930120.7	
		Genbank Sequence Report, Accession Entry X91492 for H. sapiens Chem13, submitted September 14, 1995 2005	
		Janeway and Travers (1994). Immunobiology, Current Biology Ltd., San Francisco. Pp. 10:27-10:42	
		Stryer (1988). Biochemistry, 3rd edition. Pp. 984-988	
		December 17, 2003 Third Party Observations in connection with European Application No. 97904948.3	
		February 27, 2004 Third Party Observations in connection with European Application No. 97904948.3	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/460,216
Filing Date	December 13, 1999
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffrey S. Parkin
Attorney Docket Number	50875-F-PCT-US

Sheet 6 of 29

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Alkhatib, G., et al. (1996). CC CKR5: A RANTES, MIP-1a, MIP-1β Receptor As A Fusion Cofactor For Macrophage-Tropic HIV-1. Science, 272:1955-1958	
		Alkhatib, G., et al. (1997). HIV Co-Receptor Activity Of CCR5 And Its Inhibition By Chemokines: Independence From G Protein Signaling... Virology, 234:340-348	
		Arenzana-Selsdedos, F., et al. (1996). HIV Blocked By Chemokine Antagonist. Nature, 383:400	
		Back, D.J. (1999). Pharmacological Issues Relating To Viral Resistance. Infection, 27(Suppl.2):S42-S44	
		Balzarini, et al. (1995). Suppression Of The Breakthrough Of HIV-1 In Cell Culture By Thiocarboxanilide Derivatives When Used... Proc. Natl. Acad. Sci., 92:5470-5474	
		Bleul, C.C., et al. (1991). The Lymphocyte Chemoattractant SDF-1 Is A Ligand For LESTR/Fusion And Blocks HIV-1 Entry. Nature, 382:829-832	
		Brenner, T.J., et al. (1996). Relation Between HIV-1 Syncytium Inhibition Antibodies And Clinical Outcome In Children. Lancet, 337:1001-1005	
		Broder, et al. (1996). HIV And The 7-Transmembrane Domain Receptors. Pathobiology, 64(4):171-179	
		Choe, H., et al. (1996). The Beta-Chemokine Receptors CCR3 And CCR5 Facilitate Infection By Primary HIV-1 Isolates. Cell, 85:1135-1148	
		Cocchi, F. (1995). Identification Of RANTES, MIP-1alpha And MIP-1beta As The Major HIV-Suppressive Factors Produced By CD8+ T-Cells. Science, 270:1811-1815	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/460,216
		Filing Date	December 13, 1999
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffrey S. Parkin
Sheet 7	of 29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Cruse, et al. (1995). Illustrated Dictionary Of Immunology, CRC Press, Inc, Boca Raton, FL., 143:QR180.4.C78	
		Daar, E.S. (1990). High Concentrations Of Recombinant Soluble CD4 Are Required To Neutralize Primary Human Immunodeficiency Virus Type... Proc. Natl. Acad. Sci., 87:6574-6578	
		De Clerq, et al. (1992). Potent And Selective Inhibition Of Human Immunodeficiency Virus (HIV)-1 and HIV-2 Replication By A Class Of... Proc. Natl. Acad. Sci., 89:5286-5290	
		De Clerq, et al. (1994). Highly Potent And Selective Inhibition Of Human Immunodeficiency Virus By The Bicyclam... Antimicrobial Agents and Chemotherapy, 38:668-674	
		De Clerq, et al. (1995). Antiviral Therapy For Human Immunodeficiency Virus Infections. J. Clin. Microbiol. Rev., 8(2):200-239	
		Deng, H., et al. (1996). Identification Of A Major Co-Receptor For Primary Isolates Of HIV-1. Nature, 381:661-666	
		Dikic (1996). Regulation of HIV-1 Infection by Chemokine Receptors. Acta. Med. Croatica, 50:163-168	
		Doranz, B.J., et al. (1996). A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin And Beta-Chemokine Receptors CKR-5, CKR-3 And CKR-2b As Fusion Cofactors. Cell, 85:1149-1158	
		Doranz, B.J., et al. (1997). A Small Molecule Inhibitor Directed Against The Chemokine Receptor CXCR4 Prevents Its Use As An HIV-1 Co-Receptor. J. Ex. Med., 186:1395-1400	
		Dragic, T.V., et al. (1996). HIV-1 Entry Into CD4+Cells Is Mediated By The Chemokine Receptor CC-CKR-5. Nature, 381:667-673	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet	8	of	29	Application Number	09/460,216
				Filing Date	December 13, 1999
				First Named Inventor	G.P. Allaway
				Art Unit	1648
				Examiner Name	Jeffrey S. Parkin
				Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Fahey, J.L., et al. (1992). Status Of Immune-Based Therapies In HIV Infection And AIDS. Clin. Exp. Immunol., 88:1-5	
		Feng, Y., et al. (1996). HIV-1 Entry Cofactor: Functional cDNA Cloning Of A Seven-Transmembrane, g Protein-Coupled Receptor. Science, 272:872-877	
		Flexner, C. and Hendrix, C. (1997). "Pharmacology...", in AIDS: Biology, Diagnosis,...., 4th Edition, De Vita V., et al. eds., Lippincott-Raven Publishers. Pp. 479-493	
		Fox, J.L. (1994). No Winners Against Aids. Bio/Technology, 12:128	
		Gait, M.J and Karn, J. (1995). Progress In anti-HIV Structure Based Drug Design. TIBTECH, 13:430-438	
		Gong, J.H., et al. (1995). Antagonists Of Monocyte Chemoattractant Protein 1 Identified By Modification Of Functionally Critical NH2-Terminal... J. Exp. Med., 181:631-640	
		Gong, J.H., et al. (1996). RANTES And MCP-3 Antagonists Bind Multiple Chemokine Receptors. J. Biol. Chem., 371:10521-10527	
		Hattori, T., et al. (1989). Involvement Of Trypsin-Related Cellular Protease(S) In Human Immunodeficiency Virus Type 1 Infection. FEBS Letters, 248:48-52	
		Haynes, B.F. (1996). Updates On The Issues Of HIV Vaccine Development. Ann. Med., 28:39-41	
		Howard, O.M.Z., et al. (1998). Small Molecule Inhibitor Of HIV-1 Cell Fusion Blocks Chemokine Receptor-Mediated Fusion. J. Leuk. Biol., 64:6-13	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/460,216
		Filing Date	December 13, 1999
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffrey S. Parkin
Sheet 9	of 29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Jones, S.A., et al. (1997). Chemokine Antagonists That Discriminate Between Interleukin-8 Receptors. J. Biol. Chem., 272:16166-16199	
		Klotman, et al. (1995). Transgenic Models Of HIV-1. AIDS, 9(4):313-324	
		Levy, J.A. (1996). Controlling HIV Pathogenesis: The Role Of The Non-Cytotoxic Anti-HIV Response Of CD8+ Cells. Immunology Today, 17:217-224	
		Litwin, V.M., et al. (1996). Human Immunodeficiency Virus Type 1 Membrane Fusion Mediated By A Laboratory-Adapted Strain And A... J. Virol., 70(9):6437-6441	
		Loetscher, M., et al. (1994). Cloning Of A Human Seven-Transmembrane Domain Receptor, LESTR, That Is Highly Expressed In Leukocytes. J. Biol. Chem., 269:232-237	
		McKnight, A.D., et al. (1997). Inhibition Of Human Immunodeficiency Virus Fusion By A Monoclonal Antibody To A Coreceptor (CXCR4) Is... J. Virol., 71:1692-1696	
		Mellors, J.W. (1996). Closing In On Human Immunodeficiency Virus-1. Nature Medicine, 2(3):274-275	
		Moser, B., et al. (1993). Interleukin-8 Antagonists Generated By N-Terminal Modification. J. Biol. Chem., 268:7125-7128	
		Oberg, B and Vrang, L. (1990). Screening for new agents. Eur. J. Clin. Microbiol. Infect. Dis., 9(7):466-471	
		Oberlin, E., et al. (1996). The CXC Chemokine SDF-1 is the Ligand for LESTR/fusion and prevents infection by T-cell-line-adapted HIV-1. Nature, 382: 833-835	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet 10 of 29	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	G.P. Allaway
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
Attorney Docket Number		50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Oellerich, M., (1984). Enzyme-Immunoassay: A Review. J. Clin. Chem. Clin. Biochem., 22(12):895-904	
		Proudfoot, et al. (1999). Chemokine Receptors: Future Therapeutic Targets For HIV. Biochem. Pharmacol., 57:451-463	
		Proudfoot, et al. (2000). The Strategy Of Blocking The Chemokine System To Combat Disease. Immunol. Rev., 177:246- 256	
		Raport, C.J., et al. (1996). New Members Of The Chemokine Receptor Gene Family. Journal of Leukocyte Biology, 59:18-23	
		Raport, C.J., et al. (1996). AAC50598 submitted to NCBI on April 12, 1996 (CC Chemokine Receptor 5 sequence)	
		Richman, D.D. (1996). Antiretroviral Drug-Resistance: Mechanisms, Pathogenesis, Clinical Significance. Antivir. Chemother., 4:383-395	
		Samson, M., et al. (1996). Molecular Cloning And Functional Expression Of A New Human CC-Chemokine Receptor Gene. Biochem., 35:3362-3367	
		Scarlatti, et al. (1997). In Vivo Evolution Of HIV-1 Co-Receptor Usage And Sensitivity To Chemokine-Mediated Suppression. Nature Medicine, 3(11):A2581259-1265	
		Simmons, G., et al. (1997). Potent Inhibition Of HIV-1 Infectivity In Macropages And Lymphocytes By A Novel CCR5 Antagonist. Science, 276:276-279	
		Szabo, et al. (1992). Cd4 Changes Conformation Upon Ligand Binding. J. Immunol. 149(11):3596-3604	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/460,216
Filing Date	December 13, 1999
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffrey S. Parkin
Attorney Docket Number	50875-F-PCT-US

Sheet 11

of

29

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Trkola, A., et al. (1996). CD-4 Dependent, Antibody Sensitive Interactions Between HIV-1 And Its Co-Receptor CCR-5. Nature, 384:184-187	
		Wells, T.N.C., et al. (1996). Selectivity And Antagonism Of Chemokine Receptors. Journal of Leukocyte Biology, 59:53-60	
		Wu, et al. (1997). CCR5 Levels And Expression Pattern Correlate With Infectability By Macrophagetropic HIV-1 In Vitro. J. Exp. Med., 185(9):1681-1691	
		Wu, L., et al. (1996). CD4-Induced Interaction Of Primary HIV-1 gp120 Glycoproteins With The Chemokine Receptor CCR-5. Nature, 384:179-183	
		Yarchoan, et al. (1988). "Clinical Aspects Of...", in AIDS: Etiology, Diagnosis,...., De Vita, et al., eds., Lippincott-Raven Publishers, Philadelphia. Pp.107-109	
		Yarchoan, R. and Broder, S. (1992). Correlations Between The In Vitro And The In Vivo Activity Of Anti-HIV Agents: Implications For... J. Enzyme Inhibit., 6:99-11	
		Zhang, Y.J., et al. (1994). Structure / Activity Analysis Of Human Monocyte Chemoattractant Protein-1 (MCP-1) By Mutagenesis. J. Biol. Chem., 269:15918-15924	
		February 15, 1996 Advisory Action in connection with U.S. Application Serial No. 08/169,311	
		September 13, 1995 Final Office Action in connection with U.S. Application Serial No. 08/169,311	
		November 23, 1994 Office Action in connection with U.S. Application Serial No. 08/169,311	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/460,216		
		Filing Date	December 13, 1999		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffrey S. Parkin		
Sheet	12	of	29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		August 18, 1994 Office Action in connection with U.S. Application Serial No. 08/169,311	
		July 16, 1998 Notice of Acceptance in connection with Australian Application No. 14387/95	
		November 27, 1996 Examiner's First Report in connection with Australian Application No. 14387/95	
		July 5, 2000 Notice of Acceptance in connection with Australian Application No. 62690/96	
		November 10, 1998 Examiner's First Report in connection with Australian Application No. 62690/96	
		September 14, 2006 Official Action in connection with Canadian Application No. 2,224,003	
		September 11, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
		March 8, 2006 Summons to Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 96 921 473.3	
		February 24, 2005 Provision of a Copy of the Minutes in accordance with Rule 76(4) EPC in connection with European Application No. 96 921 473.3	
		February 24, 2005 Decision to Refuse a European Patent Application in connection with European Application No. 96 921 473.3	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/460,216
Filing Date	December 13, 1999
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffrey S. Parkin
Attorney Docket Number	50875-F-PCT-US

Sheet 13 of 29

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		August 30, 2004 Summons to Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 96 921 473.3	
		December 19, 2002 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
		July 6, 2001 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
		December 20, 1999 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/973,601	
		August 3, 1999 Advisory Action in connection with U.S. Application Serial No. 08/973,601	
		March 25, 1999 Office Action in connection with U.S. Application Serial No. 08/973,601	
		June 24, 1998 Office Action in connection with U.S. Application Serial No. 08/973,601	
		January 11, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/412,284	
		December 2, 2003 Final Office Action in connection with U.S. Application Serial No. 09/412,284	
		February 3, 2003 Office Action in connection with U.S. Application Serial No. 09/412,284	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/460,216
Filing Date	December 13, 1999
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffrey S. Parkin
Attorney Docket Number	50875-F-PCT-US

Sheet 14 of 29

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		April 8, 2002 Advisory Action in connection with U.S. Application Serial No. 09/412,284	
		September 11, 2001 Final Office Action in connection with U.S. Application Serial No. 09/412,284	
		December 19, 2000 Office Action in connection with U.S. Application Serial No. 09/412,284	
		April 18, 2007 Office Action in connection with U.S. Application Serial No. 11/258,963	
		December 26, 2006 Office Action in connection with U.S. Application Serial No. 11/258,963	
		February 8, 2007 Office Action in connection with U.S. Application Serial No. 09/904,356	
		May 2, 2006 Final Office Action in connection with U.S. Application Serial No. 09/904,356	
		October 12, 2005 Office Action in connection with U.S. Application Serial No. 09/904,356	
		July 29, 2005 Advisory Action in connection with U.S. Application Serial No. 09/904,356	
		November 17, 2004 Final Office Action in connection with U.S. Application Serial No. 09/904,356	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/460,216		
		Filing Date	December 13, 1999		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffrey S. Parkin		
Sheet	15	of	29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		July 1, 2003 Office Action in connection with U.S. Application Serial No. 09/904,356	
		September 29, 2003 Advisory Action in connection with U.S. Application Serial No. 09/118,415	
		January 28, 2003 Final Office Action in connection with U.S. Application Serial No. 09/118,415	
		April 9, 2002 Office Action in connection with U.S. Application Serial No. 09/118,415	
		August 14, 2001 Advisory Action in connection with U.S. Application Serial No. 09/118,415	
		November 24, 2000 Final Office Action in connection with U.S. Application Serial No. 09/118,415	
		February 11, 2000 Office Action in connection with U.S. Application Serial No. 09/118,415	
		August 3, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/891,062	
		July 17, 2006 Notice of Allowability in connection with U.S. Application Serial No. 09/891,062	
		May 18, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/891,062	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/460,216		
		Filing Date	December 13, 1999		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffrey S. Parkin		
Sheet	16	of	29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		August 8, 2005 Office Action in connection with U.S. Application Serial No. 09/891,062	
		March 21, 2005 Office Action in connection with U.S. Application Serial No. 09/891,062	
		May 28, 2004 Advisory Action in connection with U.S. Application Serial No. 09/891,062	
		September 24, 2003 Final Office Action in connection with U.S. Application Serial No. 09/891,062	
		December 18, 2002 Office Action in connection with U.S. Application Serial No. 09/891,062	
		April 30, 2007 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 11/544,346	
		March 3, 1997 Office Action in connection with U.S. Application Serial No. 08/627,684	
		June 23, 1997 Office Action in connection with U.S. Application Serial No. 08/663,616	
		March 13, 1997 Office Action in connection with U.S. Application Serial No. 08/673,682	
		November 28, 2000 Notice of Acceptance in connection with Australian Application No. 26074/97	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/460,216		
		Filing Date	December 13, 1999		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffrey S. Parkin		
Sheet	17	of	29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		July 13, 1999 Examiner's First Report in connection with Australian Application No. 26074/97	
		October 23, 2006 Official Action in connection with Canadian Application No. 2,250,829	
		May 27, 2005 Official Action in connection with Canadian Application No. 2,250,829	
		May 4, 2007 Summons to Attend Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 97917856.3	
		January 27, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		October 21, 2005 Communication Pursuant to Article 115(2) EPC in connection with European Application No. 97917856.3	
		April 1, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		August 5, 2004 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		January 27, 2004 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		May 9, 2003 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet 18 of 29	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	G.P. Allaway
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
Attorney Docket Number		50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		March 6, 2002 Search Report Communication in connection with European Application No. 97917856.3	
		February 27, 2007 Notification of Reasons for Rejection in connection with Japanese Application No. 535610/97	
		May 19, 2006 Examiner's First Report in connection with Australian Application No. 2004233505	
		July 26, 2004 Notice of Acceptance in connection with Australian Application No. 35106/01	
		July 5, 2004 Examiner's Second Report in connection with Australian Application No. 35106/01	
		November 1, 2002 Examiner's First Report in connection with Australian Application No. 35106/01	
		December 4, 2001 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/831,823	
		January 16, 2001 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/831,823	
		September 26, 2000 Advisory Action in connection with U.S. Application Serial No. 08/831,823	
		April 11, 2000 Final Office Action in connection with U.S. Application Serial No. 08/831,823	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/460,216
		Filing Date	December 13, 1999
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffrey S. Parkin
Sheet 19	of 29	Attorney Docket Number 50875-F-PCT-US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		July 21, 1999 Final Office Action in connection with U.S. Application Serial No. 08/831,823	
		December 21, 1998 Office Action in connection with U.S. Application Serial No. 08/831,823	
		August 17, 1998 Office Action in connection with U.S. Application Serial No. 08/831,823	
		June 15, 2006 Final Office Action in connection with U.S. Application Serial No. 09/888,938	
		September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938	
		August 4, 2004 Office Action in connection with U.S. Application Serial No. 09/888,938	
		May 5, 2004 Office Action in connection with U.S. Application Serial No. 09/888,938	
		June 22, 1999 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/876,078	
		December 21, 1998 Final Office Action in connection with U.S. Application Serial No. 08/876,078	
		March 23, 1998 Office Action in connection with U.S. Application Serial No. 08/876,078	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/460,216
		Filing Date	December 13, 1999
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffrey S. Parkin
Sheet 20 of 29	Attorney Docket Number	50875-F-PCT-US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		June 16, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 98 931 261.6	
		June 17, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 98 931 261.6	
		October 17, 2006 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		February 3, 2006 Office Action in connection with U.S. Application Serial No. 09/460,216	
		July 29, 2005 Advisory Action in connection with U.S. Application Serial No. 09/460,216	
		February 09, 2005 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		September 26, 2003 Advisory Action in connection with U.S. Application Serial No. 09/460,216	
		February 27, 2003 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		October 2, 2001 Office Action in connection with U.S. Application Serial No. 09/460,216	
		September 9, 2002 Notice of Acceptance in connection with Australian Application No. 81426/98	

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/460,216
		Filing Date	December 13, 1999
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffrey S. Parkin
Sheet 21 of 29	Attorney Docket Number	50875-F-PCT-US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		February 27, 2002 Examiner's Second Report in connection with Australian Application No. 81426/98	
		February 21, 2001 Examiner's First Report in connection with Australian Application No. 81426/98	
		February 4, 1997 Office Action in connection with U.S. Application Serial No. 08/665,090	
		August 29, 2000 Notice of Allowance and Allowability in connection with 08/874,618	
		November 19, 1999 Office Action in connection with U.S. Application Serial No. 08/874,618	
		May 24, 1999 Final Office Action in connection with U.S. Application Serial No. 08/874,618	
		September 2, 1998 Office Action in connection with U.S. Application Serial No. 08/874,618	
		December 13, 2005 Final Office Action in connection with U.S. Application Serial No. 09/724,105	
		March 23, 2005 Office Action in connection with U.S. Application Serial No. 09/724,105	
		September 23, 2004 Office Action in connection with U.S. Application Serial No. 09/724,105	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/460,216
Filing Date	December 13, 1999
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffrey S. Parkin
Attorney Docket Number	50875-F-PCT-US

Sheet 22 of 29

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		May 19, 2004 Office Action in connection with U.S. Application Serial No. 09/724,105	
		December 19, 2006 Office Action in connection with U.S. Application Serial No. 11/400,497	
		August 8, 2006 Office Action in connection with U.S. Application Serial No. 11/400,497	
		May 29, 2001 Notice of Acceptance in connection with Australian Application No. 34026/97	
		September 28, 1999 Examiner's First Report in connection with Australian Application No. 34026/97	
		November 10, 2006 Official Action in connection with Canadian Application No. 2,257,991	
		May 23, 2005 Communications Pursuant to Article 96(2) EPC in connection with European Application No. 97 930 120.7	
		November 17, 2004 Communication of partial European search report under Rule 45 EPC in connection with European Application No. 97 930 120.7	
		September 9, 2004 Communication of partial European search report under Rule 46(1) EPC in connection with European Application No. 97 930 120.7	
		October 17, 2006 Notification of Reasons for Rejection in connection with Japanese Application No. 501895/98 (English translation)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/460,216
		Filing Date	December 13, 1999
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffrey S. Parkin
Sheet 23	of 29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		April 5, 2004 Notice of Acceptance in connection with Australian Application No. 21996/00	
		February 5, 2003 Examiner's First Report in connection with Australian Application No. 21996/00	
		March 29, 2006 Examiner's First Report in connection with Australian Application No. 20004205164	
		March 29, 2006 Examiner's First Report in connection with Australian Application No. 20004205165	
		March 1, 2006 Communication under Rule 51(4) EPC in connection with European Application No. 99 966 466.7	
		January 10, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 99 966 466.7	
		October 14, 2004 Communication Pursuant to Article 96(1) and Rule 51(1) EPC in connection with European Application No. 99 966 466.7	
		January 18, 2007 Office communication in connection with Mexican Application No. 1006097	
		October 13, 2005 Office communication in connection with Mexican Application No. 1006097	
		February 6, 2007 Notice of Allowability in connection with U.S. Application Serial No. 09/464,902	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet 24 of 29	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	G.P. Allaway
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		January 8, 2007 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/464,902	
		April 19, 2006 Office Action in connection with U.S. Application Serial No. 09/464,902	
		October 21, 2005 Office Action in connection with U.S. Application Serial No. 09/464,902	
		June 15, 2005 Advisory Action in connection with U.S. Application Serial No. 09/464,902	
		January 13, 2005 Final Office Action in connection with U.S. Application Serial No. 09/464,902	
		April 2, 2004 Office Action in connection with U.S. Application Serial No. 09/464,902	
		October 21, 2003 Office Action in connection with U.S. Application Serial No. 09/464,902	
		September 25, 2001 Office Action in connection with U.S. Application Serial No. 09/464,902	
		August 7, 2006 Office Action in connection with U.S. Application Serial No. 09/594,983	
		March 24, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/594,983	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/460,216		
		Filing Date	December 13, 1999		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffrey S. Parkin		
Sheet	25	of	29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		July 11, 2005 Final Office Action in connection with U.S. Application Serial No. 09/594,983	
		August 25, 2004 Office Action in connection with U.S. Application Serial No. 09/594,983	
		September 23, 2003 Notice of Allowability in connection with U.S. Application Serial No. 09/594,983	
		December 3, 2002 Final Office Action in connection with U.S. Application Serial No. 09/594,983	
		March 13, 2002 Office Action in connection with U.S. Application Serial No. 09/594,983	
		September 28, 2001 Office Action in connection with U.S. Application Serial No. 09/594,983	
		December 19, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/763,545	
		July 26, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545	
		June 13, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545	
		February 16, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

26

of

29

Complete if Known

Application Number	09/460,216
Filing Date	December 13, 1999
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffrey S. Parkin
Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		April 21, 2006 Supplementary European search report under Article 157 (2)(a) in connection with European Application No. 03 713 632.2	
		September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938	
		May 16, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/371,483	
		October 24, 2006 Office Action in connection with U.S. Application Serial No. 10/371,483	
		January 29, 2007 Examiner's First Report in connection Australian Application No. 2003217674	
		February 22, 2007 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 03 713 632.2	
		October 12, 2004 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 03 713 632.2	
		March 14, 2006 Examination Report in connection with New Zealand Application No. 534947	
		February 21, 2003 Official Action in connection with Russian Federation Application No. 2004128252/13(030609) (English Translation)	
		September 29, 2006 Grant of Patent in connection with Singaporean Application No. 200404610-8	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/460,216
		Filing Date	December 13, 1999
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffrey S. Parkin
Sheet 27 of 29	Attorney Docket Number	50875-F-PCT-US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		August 7, 2002 Office Action in connection with U.S. Application Serial No. 09/663,219	
		January 5, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/912,824	
		January 26, 2005 Final Office Action in connection with U.S. Application Serial No. 09/912,824	
		April 20, 2004 Office Action in connection with U.S. Application Serial No. 09/912,824	
		July 2, 2003 Office Action in connection with U.S. Application Serial No. 09/912,824	
		July 3, 2006 Notice of Acceptance in connection with Australian Application No. 2001290925	
		June 28, 2005 Examiner's First Report in connection with Australian Application No. 2001290925	
		May 24, 2006 Supplementary European search report under Article 157(2) (a) EPC in connection with European Application No. 01970984.9	
		February 28, 2005 Formalities Examination in connection with European Application No. 01970984.9	
		May 2, 2003 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 01970984.9	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/460,216
Filing Date	December 13, 1999
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffrey S. Parkin
Attorney Docket Number	50875-F-PCT-US

Sheet 28 of 29

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		October 25, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/828,615	
		September 13, 2005 Office Action in connection with U.S. Application Serial No. 09/828,615	
		March 2, 2005 Office Action in connection with U.S. Application Serial No. 09/828,615	
		September 17, 2004 Final Office Action in connection with U.S. Application Serial No. 09/828,615	
		February 23, 2004 Office Action in connection with U.S. Application Serial No. 09/828,615	
		September 9, 2003 Advisory Action in connection with U.S. Application Serial No. 09/828,615	
		February 21, 2003 Final Office Action in connection with U.S. Application Serial No. 09/828,615	
		June 25, 2002 Office Action in connection with U.S. Application Serial No. 09/828,615	
		June 9, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/116,797	
		April 25, 2005 Final Office Action in connection with U.S. Application Serial No. 10/116,797	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/460,216
Filing Date	December 13, 1999
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffrey S. Parkin
Attorney Docket Number	50875-F-PCT-US

Sheet 29 of 29

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		October 6, 2004 Office Action in connection with U.S. Application Serial No. 10/116,797	
		February 9, 2004 Office action in connection with U.S. Application Serial No. 10/116,797	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 29

Complete if Known

Application Number	09/460,216
Filing Date	December 13, 1999
First Named Inventor	G.P. Allaway et al.
Art Unit	1648
Examiner Name	Jeffrey S. Parkin
Attorney Docket Number	50875-F-PCT-US

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 6,692,745	02-17-2004	Olson	
		US- 6,797,811	09-28-2004	Gray	
		US- 5,126,433	12-21-1989	Maddon	
		US- 5,021,409	06-04-1991	Murrer	
		US- 5,440,021	08-05-1995	Chuntharapai	
		US- 5,504,003	04-02-1996	Haodong Li	
		US- 7,118,859	10-10-2006	V.M. Litwin et al.	
		US- 7,138,119	11-21-2006	W.C. Olson et al.	
		US- 7,060,273	06-13-2006	W.C. Olson et al.	
		US- 7,122,185	10-17-2006	W.C. Olson et al.	
		US- 6,908,734	06-21-2005	T. Dragic et al.	
		US- 2003-0166870	12-23-2004	L. Wu et al.	
		US- 2005-0118677	06-02-2005	C. Combadiere et al.	
		US- 2007-0031408 A1	02-08-2007	W.C. Olson et al.	
		US- 2007-0020280 A1	01-25-2007	W.C. Olson et al.	
		US- 2007-0025983 A1	02-01-2007	V.M. Litwin et al.	
		US- 2007-0026441 A1	02-01-2007	W.C. Olson et al.	
		US- 11/581,944	10-16-2006	W.C. Olson et al.	
		US- 2006-0194244	08-31-2006	G.P. Allaway et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		WO 07/014114	02-01-2007			
		WO 94/22477	10-13-1994			

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND**

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicants: G.P. Allaway, et al.
Serial No.: 09/460,216
Filed: December 13, 1999
Exhibit A

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	29
-------	---	----	----

Complete if Known

Application Number	09/460,216
Filing Date	December 13, 1999
First Named Inventor	G.P. Allaway et al.
Art Unit	1648
Examiner Name	Jeffrey S. Parkin
Attorney Docket Number	50875-F-PCT-US

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/460,216		
		Filing Date	December 13, 1999		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffrey S. Parkin		
Sheet	3	of	29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PCT International Preliminary Examination Report issued October 18, 1996 for International Application Publication No. WO 95/16789	
		PCT International Preliminary Examination Report issued September 5, 1997 for International Application Publication No. WO 96/41020	
		PCT International Preliminary Examination Report issued October 16, 1999 for International Application Publication No. WO 97/47319	
		PCT International Preliminary Examination Report issued September 28, 2005 for International Application Publication No. WO 03/072766	
		PCT International Preliminary Examination Report issued February 15, 2001 for International Application Publication No. WO 00/35409	
		PCT International Preliminary Examination Report issued December 24, 2003 for International Application Publication No. WO 02/083172	
		PCT International Search Report issued March 13, 1995 for International Application Publication No. WO 95/16789	
		PCT International Search Report issued October 10, 1996 for International Application Publication No. WO 96/41020	
		PCT International Search Report issued June 9, 1997 for International Application Publication No. WO 97/26009	
		PCT International Search Report issued September 3, 1997 for International Application Publication No. WO 97/47319	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/460,216
		Filing Date	December 13, 1999
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffrey S. Parkin
Sheet 4	of 29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PCT International Search Report issued September 3, 1997 for International Application Publication No. WO 97/47318	
		PCT International Search Report issued June 7, 2000 for International Application Publication No. WO 00/35409	
		PCT International Search Report issued August 13, 2003 for International Application Publication No. WO 03/072766	
		PCT International Search Report issued April 23, 2002 for International Application Publication No. WO 02/22077	
		PCT International Search Report issued July 31, 2003 for International Application Publication No. WO 02/083172	
		PCT International Preliminary Examination Report issued April 5, 2006 for International Application Publication No. WO 03/072766	
		PCT Written Opinion issued May 25, 2005 in connection with International Application Publication No. WO 03/072766	
		European Supplementary Search Report issued February 24, 2000 for European Patent Application No. 96921473.3	
		European Supplementary Search Report issued September 5, 2002 for European Patent Application No. 95905987.4	
		European Supplementary Search Report issued April 27, 2006 for European Patent Application No. 01970984.9	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/460,216		
		Filing Date	December 13, 1999		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffrey S. Parkin		
Sheet	5	of	29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		European Supplementary Search Report issued April 21, 2006 for European Application No. 03713632.2	
		European Supplementary Partial Search Report issued August 26, 2004 for European Patent Application No. 97930120.7	
		European Supplementary Partial Search Report issued November 8, 2004 for European Patent Application No. 97930120.7	
		European Supplementary Partial Search Report issued September 27, 2004 for European Application No. 99966466	
		European Patent Office Communication issued November 11, 2004 in connection with European Patent Application No. 97930120.7	
		Genbank Sequence Report, Accession Entry X91492 for H. sapiens Chem13, submitted September 14, 1995 2005	
		Janeway and Travers (1994). Immunobiology, Current Biology Ltd., San Francisco. Pp. 10:27-10:42	
		Stryer (1988). Biochemistry, 3rd edition. Pp. 984-988	
		December 17, 2003 Third Party Observations in connection with European Application No. 97904948.3	
		February 27, 2004 Third Party Observations in connection with European Application No. 97904948.3	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/460,216
		Filing Date	December 13, 1999
		First Named Inventor	G.P. Allaway
		Art Unit	1648
Examiner Name	Jeffrey S. Parkin		
Attorney Docket Number	50875-F-PCT-US		
Sheet	6	of	29

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Alkhatib, G., et al. (1996). CC CKR5: A RANTES, MIP-1a, MIP-1 β Receptor As A Fusion Cofactor For Macrophage-Tropic HIV-1. Science, 272:1955-1958	
		Alkhatib, G., et al. (1997). HIV Co-Receptor Activity Of CCR5 And Its Inhibition By Chemokines: Independence From G Protein Signaling... Virology, 234:340-348	
		Arenzana-Selsdedos, F., et al. (1996). HIV Blocked By Chemokine Antagonist. Nature, 383:400	
		Back, D.J. (1999). Pharmacological Issues Relating To Viral Resistance. Infection, 27(Suppl.2):S42-S44	
		Balzarini, et al. (1995). Suppression Of The Breakthrough Of HIV-1 In Cell Culture By Thiocarboxanilide Derivatives When Used... Proc. Natl. Acad. Sci., 92:5470-5474	
		Bleul, C.C., et al. (1991). The Lymphocyte Chemoattractant SDF-1 Is A Ligand For LESTR/Fusion And Blocks HIV-1 Entry. Nature, 382:829-832	
		Brenner, T.J., et al. (1996). Relation Between HIV-1 Syncytium Inhibition Antibodies And Clinical Outcome In Children. Lancet, 337:1001-1005	
		Broder, et al. (1996). HIV And The 7-Transmembrane Domain Receptors. Pathobiology, 64(4):171-179	
		Choe, H., et al. (1996). The Beta-Chemokine Receptors CCR3 And CCR5 Facilitate Infection By Primary HIV-1 Isolates. Cell, 85:1135-1148	
		Cocchi, F. (1995). Identification Of RANTES, MIP-1alpha And MIP-1beta As The Major HIV-Suppressive Factors Produced By CD8+ T-Cells. Science, 270:1811-1815	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/460,216
		Filing Date	December 13, 1999
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffrey S. Parkin
Sheet 7	of 29	Attorney Docket Number 50875-F-PCT-US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Cruse, et al. (1995). Illustrated Dictionary Of Immunology, CRC Press, Inc, Boca Raton, FL., 143:QR180.4.C78	
		Daar, E.S. (1990). High Concentrations Of Recombinant Soluble CD4 Are Required To Neutralize Primary Human Immunodeficiency Virus Type... Proc. Natl. Acad. Sci., 87:6574-6578	
		De Clerq, et al. (1992). Potent And Selective Inhibition Of Human Immunodeficiency Virus (HIV)-1 and HIV-2 Replication By A Class Of... Proc. Natl. Acad. Sci., 89:5286-5290	
		De Clerq, et al. (1994). Highly Potent And Selective Inhibition Of Human Immunodeficiency Virus By The Bicyclam... Antimicrobial Agents and Chemotherapy, 38:668-674	
		De Clerq, et al. (1995). Antiviral Therapy For Human Immunodeficiency Virus Infections. J. Clin. Microbiol. Rev., 8(2):200-239	
		Deng, H., et al. (1996). Identification Of A Major Co-Receptor For Primary Isolates Of HIV-1. Nature, 381:661-666	
		Dikic (1996). Regulation of HIV-1 Infection by Chemokine Receptors. Acta. Med. Croatica, 50:163-168	
		Doranz, B.J., et al. (1996). A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin And Beta-Chemokine Receptors CKR-5, CKR-3 And CKR-2b As Fusion Cofactors. Cell, 85:1149-1158	
		Doranz, B.J., et al. (1997). A Small Molecule Inhibitor Directed Against The Chemokine Receptor CXCR4 Prevents Its Use As An HIV-1 Co-Receptor. J. Ex. Med., 186:1395-1400	
		Dragic, T.V., et al. (1996). HIV-1 Entry Into CD4+Cells Is Mediated By The Chemokine Receptor CC-CKR-5. Nature, 381:667-673	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:**

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number		09/460,216
	Filing Date		December 13, 1999
	First Named Inventor		G.P. Allaway
	Art Unit		1648
	Examiner Name		Jeffrey S. Parkin
	Attorney Docket Number		50875-F-PCT-US

Sheet 8

of

29

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Fahey, J.L., et al. (1992). Status Of Immune-Based Therapies In HIV Infection And AIDS. Clin. Exp. Immunol., 88:1-5	
		Feng, Y., et al. (1996). HIV-1 Entry Cofactor: Functional cDNA Cloning Of A Seven-Transmembrane, g Protein-Coupled Receptor. Science, 272:872-877	
		Flexner, C. and Hendrix, C. (1997). "Pharmacology...", in AIDS: Biology, Diagnosis, ..., 4th Edition, De Vita V., et al. eds., Lippincott-Raven Publishers. Pp. 479-493	
		Fox, J.L. (1994). No Winners Against Aids. Bio/Technology, 12:128	
		Gait, M.J and Karn, J. (1995). Progress In anti-HIV Structure Based Drug Design. TIBTECH, 13:430-438	
		Gong, J.H., et al. (1995). Antagonists Of Monocyte Chemoattractant Protein 1 Identified By Modification Of Functionally Critical NH2-Terminal... J. Exp. Med., 181:631-640	
		Gong, J.H., et al. (1996). RANTES And MCP-3 Antagonists Bind Multiple Chemokine Receptors. J. Biol. Chem., 371:10521-10527	
		Hattori, T., et al. (1989). Involvement Of Trypsin-Related Cellular Protease(S) In Human Immunodeficiency Virus Type 1 Infection. FEBS Letters, 248:48-52	
		Haynes, B.F. (1996). Updates On The Issues Of HIV Vaccine Development. Ann. Med., 28:39-41	
		Howard, O.M.Z., et al. (1998). Small Molecule Inhibitor Of HIV-1 Cell Fusion Blocks Chemokine Receptor-Mediated Fusion. J. Leuk. Biol., 64:6-13	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/460,216
		Filing Date	December 13, 1999
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffrey S. Parkin
Sheet 9	of 29	Attorney Docket Number 50875-F-PCT-US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Jones, S.A., et al. (1997). Chemokine Antagonists That Discriminate Between Interleukin-8 Receptors. J. Biol. Chem., 272:16166-16199	
		Klotman, et al. (1995). Transgenic Models Of HIV-1. AIDS, 9(4):313-324	
		Levy, J.A. (1996). Controlling HIV Pathogenesis: The Role Of The Non-Cytotoxic Anti-HIV Response Of CD8+ Cells. Immunology Today, 17:217-224	
		Litwin, V.M., et al. (1996). Human Immunodeficiency Virus Type 1 Membrane Fusion Mediated By A Laboratory-Adapted Strain And A... J. Virol., 70(9):6437-6441	
		Loetscher, M., et al. (1994). Cloning Of A Human Seven-Transmembrane Domain Receptor, LESTR, That Is Highly Expressed In Leukocytes. J. Biol. Chem., 269:232-237	
		McKnight, A.D., et al. (1997). Inhibition Of Human Immunodeficiency Virus Fusion By A Monoclonal Antibody To A Coreceptor (CXCR4) Is... J. Virol., 71:1692-1696	
		Mellors, J.W. (1996). Closing In On Human Immunodeficiency Virus-1. Nature Medicine, 2(3):274-275	
		Moser, B., et al. (1993). Interleukin-8 Antagonists Generated By N-Terminal Modification. J. Biol. Chem., 268:7125-7128	
		Oberg, B and Vrang, L. (1990). Screening for new agents. Eur. J. Clin. Microbiol. Infect. Dis., 9(7):466-471	
		Oberlin, E., et al. (1996). The CXC Chemokine SDF-1 is the Ligand for LESTR/fusion and prevents infection by T-cell-line-adapted HIV-1. Nature, 382: 833-835	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/460,216
		Filing Date	December 13, 1999
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffrey S. Parkin
Sheet 10 of 29	Attorney Docket Number		50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Oellerich, M., (1984). Enzyme-Immunoassay: A Review. J. Clin. Chem. Clin. Biochem., 22(12):895-904	
		Proudfoot, et al. (1999). Chemokine Receptors: Future Therapeutic Targets For HIV. Biochem. Pharmacol., 57:451-463	
		Proudfoot, et al. (2000). The Strategy Of Blocking The Chemokine System To Combat Disease. Immunol. Rev., 177:246- 256	
		Raport, C.J., et al. (1996). New Members Of The Chemokine Receptor Gene Family. Journal of Leukocyte Biology, 59:18-23	
		Raport, C.J., et al. (1996). AAC50598 submitted to NCBI on April 12, 1996 (CC Chemokine Receptor 5 sequence)	
		Richman, D.D. (1996). Antiretroviral Drug-Resistance: Mechanisms, Pathogenesis, Clinical Significance. Antivir. Chemother., 4:383-395	
		Samson, M., et al. (1996). Molecular Cloning And Functional Expression Of A New Human CC-Chemokine Receptor Gene. Biochem., 35:3362-3367	
		Scarlatti, et al. (1997). In Vivo Evolution Of HIV-1 Co-Receptor Usage And Sensitivity To Chemokine-Mediated Suppression. Nature Medicine, 3(11):A2581259-1265	
		Simmons, G., et al. (1997). Potent Inhibition Of HIV-1 Infectivity In Macropages And Lymphocytes By A Novel CCR5 Antagonist. Science, 276:276-279	
		Szabo, et al. (1992). Cd4 Changes Conformation Upon Ligand Binding. J. Immunol. 149(11):3596-3604	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/460,216		
		Filing Date	December 13, 1999		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffrey S. Parkin		
Sheet	11	of	29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Trkola, A., et al. (1996). CD-4 Dependent, Antibody Sensitive Interactions Between HIV-1 And Its Co-Receptor CCR-5. Nature, 384:184-187	
		Wells, T.N.C., et al. (1996). Selectivity And Antagonism Of Chemokine Receptors. Journal of Leukocyte Biology, 59:53-60	
		Wu, et al. (1997). CCR5 Levels And Expression Pattern Correlate With Infectability By Macrophagetropic HIV-1 In Vitro. J. Exp. Med., 185(9):1681-1691	
		Wu, L., et al. (1996). CD4-Induced Interaction Of Primary HIV-1 gp120 Glycoproteins With The Chemokine Receptor CCR-5. Nature, 384:179-183	
		Yarchoan, et al. (1988). "Clinical Aspects Of...", in AIDS: Etiology, Diagnosis,..., De Vita, et al., eds., Lippincott-Raven Publishers, Philadelphia. Pp.107-109	
		Yarchoan, R. and Broder, S. (1992). Correlations Between The In Vitro And The In Vivo Activity Of Anti-HIV Agents: Implications For... J. Enzyme Inhibit., 6:99-11	
		Zhang, Y.J., et al. (1994). Structure / Activity Analysis Of Human Monocyte Chemoattractant Protein-1 (MCP-1) By Mutagenesis. J. Biol. Chem., 269:15918-15924	
		February 15, 1996 Advisory Action in connection with U.S. Application Serial No. 08/169,311	
		September 13, 1995 Final Office Action in connection with U.S. Application Serial No. 08/169,311	
		November 23, 1994 Office Action in connection with U.S. Application Serial No. 08/169,311	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/460,216		
		Filing Date	December 13, 1999		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffrey S. Parkin		
Sheet	12	of	29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		August 18, 1994 Office Action in connection with U.S. Application Serial No. 08/169,311	
		July 16, 1998 Notice of Acceptance in connection with Australian Application No. 14387/95	
		November 27, 1996 Examiner's First Report in connection with Australian Application No. 14387/95	
		July 5, 2000 Notice of Acceptance in connection with Australian Application No. 62690/96	
		November 10, 1998 Examiner's First Report in connection with Australian Application No. 62690/96	
		September 14, 2006 Official Action in connection with Canadian Application No. 2,224,003	
		September 11, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
		March 8, 2006 Summons to Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 96 921 473.3	
		February 24, 2005 Provision of a Copy of the Minutes in accordance with Rule 76(4) EPC in connection with European Application No. 96 921 473.3	
		February 24, 2005 Decision to Refuse a European Patent Application in connection with European Application No. 96 921 473.3	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/460,216		
		Filing Date	December 13, 1999		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffrey S. Parkin		
Sheet	13	of	29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		August 30, 2004 Summons to Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 96 921 473.3	
		December 19, 2002 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
		July 6, 2001 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
		December 20, 1999 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/973,601	
		August 3, 1999 Advisory Action in connection with U.S. Application Serial No. 08/973,601	
		March 25, 1999 Office Action in connection with U.S. Application Serial No. 08/973,601	
		June 24, 1998 Office Action in connection with U.S. Application Serial No. 08/973,601	
		January 11, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/412,284	
		December 2, 2003 Final Office Action in connection with U.S. Application Serial No. 09/412,284	
		February 3, 2003 Office Action in connection with U.S. Application Serial No. 09/412,284	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/460,216		
		Filing Date	December 13, 1999		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffrey S. Parkin		
Sheet	14	of	29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		April 8, 2002 Advisory Action in connection with U.S. Application Serial No. 09/412,284	
		September 11, 2001 Final Office Action in connection with U.S. Application Serial No. 09/412,284	
		December 19, 2000 Office Action in connection with U.S. Application Serial No. 09/412,284	
		April 18, 2007 Office Action in connection with U.S. Application Serial No. 11/258,963	
		December 26, 2006 Office Action in connection with U.S. Application Serial No. 11/258,963	
		February 8, 2007 Office Action in connection with U.S. Application Serial No. 09/904,356	
		May 2, 2006 Final Office Action in connection with U.S. Application Serial No. 09/904,356	
		October 12, 2005 Office Action in connection with U.S. Application Serial No. 09/904,356	
		July 29, 2005 Advisory Action in connection with U.S. Application Serial No. 09/904,356	
		November 17, 2004 Final Office Action in connection with U.S. Application Serial No. 09/904,356	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/460,216		
		Filing Date	December 13, 1999		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffrey S. Parkin		
Sheet	15	of	29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		July 1, 2003 Office Action in connection with U.S. Application Serial No. 09/904,356	
		September 29, 2003 Advisory Action in connection with U.S. Application Serial No. 09/118,415	
		January 28, 2003 Final Office Action in connection with U.S. Application Serial No. 09/118,415	
		April 9, 2002 Office Action in connection with U.S. Application Serial No. 09/118,415	
		August 14, 2001 Advisory Action in connection with U.S. Application Serial No. 09/118,415	
		November 24, 2000 Final Office Action in connection with U.S. Application Serial No. 09/118,415	
		February 11, 2000 Office Action in connection with U.S. Application Serial No. 09/118,415	
		August 3, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/891,062	
		July 17, 2006 Notice of Allowability in connection with U.S. Application Serial No. 09/891,062	
		May 18, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/891,062	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/460,216		
		Filing Date	December 13, 1999		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffrey S. Parkin		
Sheet	16	of	29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		August 8, 2005 Office Action in connection with U.S. Application Serial No. 09/891,062	
		March 21, 2005 Office Action in connection with U.S. Application Serial No. 09/891,062	
		May 28, 2004 Advisory Action in connection with U.S. Application Serial No. 09/891,062	
		September 24, 2003 Final Office Action in connection with U.S. Application Serial No. 09/891,062	
		December 18, 2002 Office Action in connection with U.S. Application Serial No. 09/891,062	
		April 30, 2007 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 11/544,346	
		March 3, 1997 Office Action in connection with U.S. Application Serial No. 08/627,684	
		June 23, 1997 Office Action in connection with U.S. Application Serial No. 08/663,616	
		March 13, 1997 Office Action in connection with U.S. Application Serial No. 08/673,682	
		November 28, 2000 Notice of Acceptance in connection with Australian Application No. 26074/97	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet 17 of 29	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	G.P. Allaway
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
Attorney Docket Number		50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		July 13, 1999 Examiner's First Report in connection with Australian Application No. 26074/97	
		October 23, 2006 Official Action in connection with Canadian Application No. 2,250,829	
		May 27, 2005 Official Action in connection with Canadian Application No. 2,250,829	
		May 4, 2007 Summons to Attend Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 97917856.3	
		January 27, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		October 21, 2005 Communication Pursuant to Article 115(2) EPC in connection with European Application No. 97917856.3	
		April 1, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		August 5, 2004 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		January 27, 2004 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		May 9, 2003 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number		09/460,216
	Filing Date		December 13, 1999
	First Named Inventor		G.P. Allaway
	Art Unit		1648
	Examiner Name		Jeffrey S. Parkin
Sheet	18	of	29
Attorney Docket Number			50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		March 6, 2002 Search Report Communication in connection with European Application No. 97917856.3	
		February 27, 2007 Notification of Reasons for Rejection in connection with Japanese Application No. 535610/97	
		May 19, 2006 Examiner's First Report in connection with Australian Application No. 2004233505	
		July 26, 2004 Notice of Acceptance in connection with Australian Application No. 35106/01	
		July 5, 2004 Examiner's Second Report in connection with Australian Application No. 35106/01	
		November 1, 2002 Examiner's First Report in connection with Australian Application No. 35106/01	
		December 4, 2001 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/831,823	
		January 16, 2001 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/831,823	
		September 26, 2000 Advisory Action in connection with U.S. Application Serial No. 08/831,823	
		April 11, 2000 Final Office Action in connection with U.S. Application Serial No. 08/831,823	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/460,216		
		Filing Date	December 13, 1999		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffrey S. Parkin		
Sheet	19	of	29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		July 21, 1999 Final Office Action in connection with U.S. Application Serial No. 08/831,823	
		December 21, 1998 Office Action in connection with U.S. Application Serial No. 08/831,823	
		August 17, 1998 Office Action in connection with U.S. Application Serial No. 08/831,823	
		June 15, 2006 Final Office Action in connection with U.S. Application Serial No. 09/888,938	
		September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938	
		August 4, 2004 Office Action in connection with U.S. Application Serial No. 09/888,938	
		May 5, 2004 Office Action in connection with U.S. Application Serial No. 09/888,938	
		June 22, 1999 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/876,078	
		December 21, 1998 Final Office Action in connection with U.S. Application Serial No. 08/876,078	
		March 23, 1998 Office Action in connection with U.S. Application Serial No. 08/876,078	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	09/460,216
		Filing Date	December 13, 1999
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffrey S. Parkin
Sheet 20 of 29	Attorney Docket Number	50875-F-PCT-US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		June 16, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 98 931 261.6	
		June 17, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 98 931 261.6	
		October 17, 2006 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		February 3, 2006 Office Action in connection with U.S. Application Serial No. 09/460,216	
		July 29, 2005 Advisory Action in connection with U.S. Application Serial No. 09/460,216	
		February 09, 2005 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		September 26, 2003 Advisory Action in connection with U.S. Application Serial No. 09/460,216	
		February 27, 2003 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		October 2, 2001 Office Action in connection with U.S. Application Serial No. 09/460,216	
		September 9, 2002 Notice of Acceptance in connection with Australian Application No. 81426/98	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/460,216		
		Filing Date	December 13, 1999		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffrey S. Parkin		
Sheet	21	of	29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		February 27, 2002 Examiner's Second Report in connection with Australian Application No. 81426/98	
		February 21, 2001 Examiner's First Report in connection with Australian Application No. 81426/98	
		February 4, 1997 Office Action in connection with U.S. Application Serial No. 08/665,090	
		August 29, 2000 Notice of Allowance and Allowability in connection with 08/874,618	
		November 19, 1999 Office Action in connection with U.S. Application Serial No. 08/874,618	
		May 24, 1999 Final Office Action in connection with U.S. Application Serial No. 08/874,618	
		September 2, 1998 Office Action in connection with U.S. Application Serial No. 08/874,618	
		December 13, 2005 Final Office Action in connection with U.S. Application Serial No. 09/724,105	
		March 23, 2005 Office Action in connection with U.S. Application Serial No. 09/724,105	
		September 23, 2004 Office Action in connection with U.S. Application Serial No. 09/724,105	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/460,216
		Filing Date	December 13, 1999
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffrey S. Parkin
Sheet 22 of 29	Attorney Docket Number	50875-F-PCT-US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		May 19, 2004 Office Action in connection with U.S. Application Serial No. 09/724,105	
		December 19, 2006 Office Action in connection with U.S. Application Serial No. 11/400,497	
		August 8, 2006 Office Action in connection with U.S. Application Serial No. 11/400,497	
		May 29, 2001 Notice of Acceptance in connection with Australian Application No. 34026/97	
		September 28, 1999 Examiner's First Report in connection with Australian Application No. 34026/97	
		November 10, 2006 Official Action in connection with Canadian Application No. 2,257,991	
		May 23, 2005 Communications Pursuant to Article 96(2) EPC in connection with European Application No. 97 930 120.7	
		November 17, 2004 Communication of partial European search report under Rule 45 EPC in connection with European Application No. 97 930 120.7	
		September 9, 2004 Communication of partial European search report under Rule 46(1) EPC in connection with European Application No. 97 930 120.7	
		October 17, 2006 Notification of Reasons for Rejection in connection with Japanese Application No. 501895/98 (English translation)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/460,216
		Filing Date	December 13, 1999
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffrey S. Parkin
Sheet 23	of 29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		April 5, 2004 Notice of Acceptance in connection with Australian Application No. 21996/00	
		February 5, 2003 Examiner's First Report in connection with Australian Application No. 21996/00	
		March 29, 2006 Examiner's First Report in connection with Australian Application No. 20004205164	
		March 29, 2006 Examiner's First Report in connection with Australian Application No. 20004205165	
		March 1, 2006 Communication under Rule 51(4) EPC in connection with European Application No. 99 966 466.7	
		January 10, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 99 966 466.7	
		October 14, 2004 Communication Pursuant to Article 96(1) and Rule 51(1) EPC in connection with European Application No. 99 966 466.7	
		January 18, 2007 Office communication in connection with Mexican Application No. 1006097	
		October 13, 2005 Office communication in connection with Mexican Application No. 1006097	
		February 6, 2007 Notice of Allowability in connection with U.S. Application Serial No. 09/464,902	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet 24 of 29	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	G.P. Allaway
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		January 8, 2007 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/464,902	
		April 19, 2006 Office Action in connection with U.S. Application Serial No. 09/464,902	
		October 21, 2005 Office Action in connection with U.S. Application Serial No. 09/464,902	
		June 15, 2005 Advisory Action in connection with U.S. Application Serial No. 09/464,902	
		January 13, 2005 Final Office Action in connection with U.S. Application Serial No. 09/464,902	
		April 2, 2004 Office Action in connection with U.S. Application Serial No. 09/464,902	
		October 21, 2003 Office Action in connection with U.S. Application Serial No. 09/464,902	
		September 25, 2001 Office Action in connection with U.S. Application Serial No. 09/464,902	
		August 7, 2006 Office Action in connection with U.S. Application Serial No. 09/594,983	
		March 24, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/594,983	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/460,216		
		Filing Date	December 13, 1999		
		First Named Inventor	G.P. Allaway		
		Art Unit	1648		
		Examiner Name	Jeffrey S. Parkin		
Sheet	25	of	29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		July 11, 2005 Final Office Action in connection with U.S. Application Serial No. 09/594,983	
		August 25, 2004 Office Action in connection with U.S. Application Serial No. 09/594,983	
		September 23, 2003 Notice of Allowability in connection with U.S. Application Serial No. 09/594,983	
		December 3, 2002 Final Office Action in connection with U.S. Application Serial No. 09/594,983	
		March 13, 2002 Office Action in connection with U.S. Application Serial No. 09/594,983	
		September 28, 2001 Office Action in connection with U.S. Application Serial No. 09/594,983	
		December 19, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/763,545	
		July 26, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545	
		June 13, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545	
		February 16, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/460,216
		Filing Date	December 13, 1999
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffrey S. Parkin
Sheet 26	of 29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		April 21, 2006 Supplementary European search report under Article 157 (2)(a) in connection with European Application No. 03 713 632.2	
		September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938	
		May 16, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/371,483	
		October 24, 2006 Office Action in connection with U.S. Application Serial No. 10/371,483	
		January 29, 2007 Examiner's First Report in connection Australian Application No. 2003217674	
		February 22, 2007 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 03 713 632.2	
		October 12, 2004 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 03 713 632.2	
		March 14, 2006 Examination Report in connection with New Zealand Application No. 534947	
		February 21, 2003 Official Action in connection with Russian Federation Application No. 2004128252/13(030609) (English Translation)	
		September 29, 2006 Grant of Patent in connection with Singaporean Application No. 200404610-8	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/460,216
		Filing Date	December 13, 1999
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffrey S. Parkin
Sheet 27	of 29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		August 7, 2002 Office Action in connection with U.S. Application Serial No. 09/663,219	
		January 5, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/912,824	
		January 26, 2005 Final Office Action in connection with U.S. Application Serial No. 09/912,824	
		April 20, 2004 Office Action in connection with U.S. Application Serial No. 09/912,824	
		July 2, 2003 Office Action in connection with U.S. Application Serial No. 09/912,824	
		July 3, 2006 Notice of Acceptance in connection with Australian Application No. 2001290925	
		June 28, 2005 Examiner's First Report in connection with Australian Application No. 2001290925	
		May 24, 2006 Supplementary European search report under Article 157(2) (a) EPC in connection with European Application No. 01970984.9	
		February 28, 2005 Formalities Examination in connection with European Application No. 01970984.9	
		May 2, 2003 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 01970984.9	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/460,216
		Filing Date	December 13, 1999
		First Named Inventor	G.P. Allaway
		Art Unit	1648
		Examiner Name	Jeffrey S. Parkin
Sheet 28	of 29	Attorney Docket Number	50875-F-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		October 25, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/828,615	
		September 13, 2005 Office Action in connection with U.S. Application Serial No. 09/828,615	
		March 2, 2005 Office Action in connection with U.S. Application Serial No. 09/828,615	
		September 17, 2004 Final Office Action in connection with U.S. Application Serial No. 09/828,615	
		February 23, 2004 Office Action in connection with U.S. Application Serial No. 09/828,615	
		September 9, 2003 Advisory Action in connection with U.S. Application Serial No. 09/828,615	
		February 21, 2003 Final Office Action in connection with U.S. Application Serial No. 09/828,615	
		June 25, 2002 Office Action in connection with U.S. Application Serial No. 09/828,615	
		June 9, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/116,797	
		April 25, 2005 Final Office Action in connection with U.S. Application Serial No. 10/116,797	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/460,216
Filing Date	December 13, 1999
First Named Inventor	G.P. Allaway
Art Unit	1648
Examiner Name	Jeffrey S. Parkin
Attorney Docket Number	50875-F-PCT-US

Sheet 29 of 29

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		October 6, 2004 Office Action in connection with U.S. Application Serial No. 10/116,797	
		February 9, 2004 Office action in connection with U.S. Application Serial No. 10/116,797	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.